Cool the Inflamed Brain: A Novel Anti-inflammatory Strategy for the Treatment of Major Depressive Disorder


Cite item

Full Text

Abstract

Background:Abundant evidence suggests that inflammatory cytokines contribute to the symptoms of major depressive disorder (MDD) by altering neurotransmission, neuroplasticity, and neuroendocrine processes. Given the unsatisfactory response and remission of monoaminergic antidepressants, anti-inflammatory therapy is proposed as a feasible way to augment the antidepressant effect. Recently, there have been emerging studies investigating the efficiency and efficacy of anti-inflammatory agents in the treatment of MDD and depressive symptoms comorbid with somatic diseases.

Methods:In this narrative review, prospective clinical trials focusing on anti-inflammatory treatment for depression have been comprehensively searched and screened. Based on the included studies, we summarize the rationale for the anti-inflammatory therapy of depression and discuss the utilities and confusions regarding the anti-inflammatory strategy for MDD.

Results:This review included over 45 eligible trials. For ease of discussion, we have grouped them into six categories based on their mechanism of action, and added some other anti-inflammatory modalities, including Chinese herbal medicine and non-drug therapy. Pooled results suggest that anti-inflammatory therapy is effective in improving depressive symptoms, whether used as monotherapy or add-on therapy. However, there remain confusions in the application of anti-inflammatory therapy for MDD.

Conclusion:Based on current clinical evidence, anti-inflammatory therapy is a promisingly effective treatment for depression. This study proposes a novel strategy for clinical diagnosis, disease classification, personalized treatment, and prognostic prediction of depression. Inflammatory biomarkers are recommended to be assessed at the first admission of MDD patients, and anti-inflammatory therapy are recommended to be included in the clinical practice guidelines for diagnosis and treatment. Those patients with high levels of baseline inflammation (e.g., CRP > 3 mg/L) may benefit from adjunctive anti-inflammatory therapy.

About the authors

Wen-Jun Su

Department of Stress Medicine, Faculty of Psychology, Second Military Medical University

Email: info@benthamscience.net

Ting Hu

Department of Stress Medicine, Faculty of Psychology, Second Military Medical University

Email: info@benthamscience.net

Chun-Lei Jiang

Department of Stress Medicine, Faculty of Psychology, Second Military Medical University

Author for correspondence.
Email: info@benthamscience.net

References

  1. World Health Organization. Factsheets: Depression., Available from: www.who.int/news-room/fact-sheets/detail/depression (Accessed on: Aug 31 2022).
  2. James, S.L.; Abate, D.; Abate, K.H.; Abay, S.M.; Abbafati, C.; Abbasi, N.; Abbastabar, H.; Abd-Allah, F.; Abdela, J.; Abdelalim, A.; Abdollahpour, I.; Abdulkader, R.S.; Abebe, Z.; Abera, S.F.; Abil, O.Z.; Abraha, H.N.; Abu-Raddad, L.J.; Abu-Rmeileh, N.M.E.; Accrombessi, M.M.K.; Acharya, D.; Acharya, P.; Ackerman, I.N.; Adamu, A.A.; Adebayo, O.M.; Adekanmbi, V.; Adetokunboh, O.O.; Adib, M.G.; Adsuar, J.C.; Afanvi, K.A.; Afarideh, M.; Afshin, A.; Agarwal, G.; Agesa, K.M.; Aggarwal, R.; Aghayan, S.A.; Agrawal, S.; Ahmadi, A.; Ahmadi, M.; Ahmadieh, H.; Ahmed, M.B.; Aichour, A.N.; Aichour, I.; Aichour, M.T.E.; Akinyemiju, T.; Akseer, N.; Al-Aly, Z.; Al-Eyadhy, A.; Al-Mekhlafi, H.M.; Al-Raddadi, R.M.; Alahdab, F.; Alam, K.; Alam, T.; Alashi, A.; Alavian, S.M.; Alene, K.A.; Alijanzadeh, M.; Alizadeh-Navaei, R.; Aljunid, S.M.; Alkerwi, A.; Alla, F.; Allebeck, P.; Alouani, M.M.L.; Altirkawi, K.; Alvis-Guzman, N.; Amare, A.T.; Aminde, L.N.; Ammar, W.; Amoako, Y.A.; Anber, N.H.; Andrei, C.L.; Androudi, S.; Animut, M.D.; Anjomshoa, M.; Ansha, M.G.; Antonio, C.A.T.; Anwari, P.; Arabloo, J.; Arauz, A.; Aremu, O.; Ariani, F.; Armoon, B.; Ärnlöv, J.; Arora, A.; Artaman, A.; Aryal, K.K.; Asayesh, H.; Asghar, R.J.; Ataro, Z.; Atre, S.R.; Ausloos, M.; Avila-Burgos, L.; Avokpaho, E.F.G.A.; Awasthi, A.; Ayala Quintanilla, B.P.; Ayer, R.; Azzopardi, P.S.; Babazadeh, A.; Badali, H.; Badawi, A.; Bali, A.G.; Ballesteros, K.E.; Ballew, S.H.; Banach, M.; Banoub, J.A.M.; Banstola, A.; Barac, A.; Barboza, M.A.; Barker-Collo, S.L.; Bärnighausen, T.W.; Barrero, L.H.; Baune, B.T.; Bazargan-Hejazi, S.; Bedi, N.; Beghi, E.; Behzadifar, M.; Behzadifar, M.; Béjot, Y.; Belachew, A.B.; Belay, Y.A.; Bell, M.L.; Bello, A.K.; Bensenor, I.M.; Bernabe, E.; Bernstein, R.S.; Beuran, M.; Beyranvand, T.; Bhala, N.; Bhattarai, S.; Bhaumik, S.; Bhutta, Z.A.; Biadgo, B.; Bijani, A.; Bikbov, B.; Bilano, V.; Bililign, N.; Bin Sayeed, M.S.; Bisanzio, D.; Blacker, B.F.; Blyth, F.M.; Bou-Orm, I.R.; Boufous, S.; Bourne, R.; Brady, O.J.; Brainin, M.; Brant, L.C.; Brazinova, A.; Breitborde, N.J.K.; Brenner, H.; Briant, P.S.; Briggs, A.M.; Briko, A.N.; Britton, G.; Brugha, T.; Buchbinder, R.; Busse, R.; Butt, Z.A.; Cahuana-Hurtado, L.; Cano, J.; Cárdenas, R.; Carrero, J.J.; Carter, A.; Carvalho, F.; Castañeda-Orjuela, C.A.; Castillo Rivas, J.; Castro, F.; Catalá-López, F.; Cercy, K.M.; Cerin, E.; Chaiah, Y.; Chang, A.R.; Chang, H-Y.; Chang, J-C.; Charlson, F.J.; Chattopadhyay, A.; Chattu, V.K.; Chaturvedi, P.; Chiang, P.P-C.; Chin, K.L.; Chitheer, A.; Choi, J-Y.J.; Chowdhury, R.; Christensen, H.; Christopher, D.J.; Cicuttini, F.M.; Ciobanu, L.G.; Cirillo, M.; Claro, R.M.; Collado-Mateo, D.; Cooper, C.; Coresh, J.; Cortesi, P.A.; Cortinovis, M.; Costa, M.; Cousin, E.; Criqui, M.H.; Cromwell, E.A.; Cross, M.; Crump, J.A.; Dadi, A.F.; Dandona, L.; Dandona, R.; Dargan, P.I.; Daryani, A.; Das Gupta, R.; Das Neves, J.; Dasa, T.T.; Davey, G.; Davis, A.C.; Davitoiu, D.V.; De Courten, B.; De La Hoz, F.P.; De Leo, D.; De Neve, J-W.; Degefa, M.G.; Degenhardt, L.; Deiparine, S.; Dellavalle, R.P.; Demoz, G.T.; Deribe, K.; Dervenis, N.; Des Jarlais, D.C.; Dessie, G.A.; Dey, S.; Dharmaratne, S.D.; Dinberu, M.T.; Dirac, M.A.; Djalalinia, S.; Doan, L.; Dokova, K.; Doku, D.T.; Dorsey, E.R.; Doyle, K.E.; Driscoll, T.R.; Dubey, M.; Dubljanin, E.; Duken, E.E.; Duncan, B.B.; Duraes, A.R.; Ebrahimi, H.; Ebrahimpour, S.; Echko, M.M.; Edvardsson, D.; Effiong, A.; Ehrlich, J.R.; El Bcheraoui, C.; El Sayed Zaki, M.; El-Khatib, Z.; Elkout, H.; Elyazar, I.R.F.; Enayati, A.; Endries, A.Y.; Er, B.; Erskine, H.E.; Eshrati, B.; Eskandarieh, S.; Esteghamati, A.; Esteghamati, S.; Fakhim, H.; Fallah Omrani, V.; Faramarzi, M.; Fareed, M.; Farhadi, F.; Farid, T.A.; Farinha, C.S.E.; Farioli, A.; Faro, A.; Farvid, M.S.; Farzadfar, F.; Feigin, V.L.; Fentahun, N.; Fereshtehnejad, S-M.; Fernandes, E.; Fernandes, J.C.; Ferrari, A.J.; Feyissa, G.T.; Filip, I.; Fischer, F.; Fitzmaurice, C.; Foigt, N.A.; Foreman, K.J.; Fox, J.; Frank, T.D.; Fukumoto, T.; Fullman, N.; Fürst, T.; Furtado, J.M.; Futran, N.D.; Gall, S.; Ganji, M.; Gankpe, F.G.; Garcia-Basteiro, A.L.; Gardner, W.M.; Gebre, A.K.; Gebremedhin, A.T.; Gebremichael, T.G.; Gelano, T.F.; Geleijnse, J.M.; Genova-Maleras, R.; Geramo, Y.C.D.; Gething, P.W.; Gezae, K.E.; Ghadiri, K.; Ghasemi Falavarjani, K.; Ghasemi-Kasman, M.; Ghimire, M.; Ghosh, R.; Ghoshal, A.G.; Giampaoli, S.; Gill, P.S.; Gill, T.K.; Ginawi, I.A.; Giussani, G.; Gnedovskaya, E.V.; Goldberg, E.M.; Goli, S.; Gómez-Dantés, H.; Gona, P.N.; Gopalani, S.V.; Gorman, T.M.; Goulart, A.C.; Goulart, B.N.G.; Grada, A.; Grams, M.E.; Grosso, G.; Gugnani, H.C.; Guo, Y.; Gupta, P.C.; Gupta, R.; Gupta, R.; Gupta, T.; Gyawali, B.; Haagsma, J.A.; Hachinski, V.; Hafezi-Nejad, N.; Haghparast Bidgoli, H.; Hagos, T.B.; Hailu, G.B.; Haj-Mirzaian, A.; Haj-Mirzaian, A.; Hamadeh, R.R.; Hamidi, S.; Handal, A.J.; Hankey, G.J.; Hao, Y.; Harb, H.L.; Harikrishnan, S.; Haro, J.M.; Hasan, M.; Hassankhani, H.; Hassen, H.Y.; Havmoeller, R.; Hawley, C.N.; Hay, R.J.; Hay, S.I.; Hedayatizadeh-Omran, A.; Heibati, B.; Hendrie, D.; Henok, A.; Herteliu, C.; Heydarpour, S.; Hibstu, D.T.; Hoang, H.T.; Hoek, H.W.; Hoffman, H.J.; Hole, M.K.; Homaie Rad, E.; Hoogar, P.; Hosgood, H.D.; Hosseini, S.M.; Hosseinzadeh, M.; Hostiuc, M.; Hostiuc, S.; Hotez, P.J.; Hoy, D.G.; Hsairi, M.; Htet, A.S.; Hu, G.; Huang, J.J.; Huynh, C.K.; Iburg, K.M.; Ikeda, C.T.; Ileanu, B.; Ilesanmi, O.S.; Iqbal, U.; Irvani, S.S.N.; Irvine, C.M.S.; Islam, S.M.S.; Islami, F.; Jacobsen, K.H.; Jahangiry, L.; Jahanmehr, N.; Jain, S.K.; Jakovljevic, M.; Javanbakht, M.; Jayatilleke, A.U.; Jeemon, P.; Jha, R.P.; Jha, V.; Ji, J.S.; Johnson, C.O.; Jonas, J.B.; Jozwiak, J.J.; Jungari, S.B.; Jürisson, M.; Kabir, Z.; Kadel, R.; Kahsay, A.; Kalani, R.; Kanchan, T.; Karami, M.; Karami Matin, B.; Karch, A.; Karema, C.; Karimi, N.; Karimi, S.M.; Kasaeian, A.; Kassa, D.H.; Kassa, G.M.; Kassa, T.D.; Kassebaum, N.J.; Katikireddi, S.V.; Kawakami, N.; Karyani, A.K.; Keighobadi, M.M.; Keiyoro, P.N.; Kemmer, L.; Kemp, G.R.; Kengne, A.P.; Keren, A.; Khader, Y.S.; Khafaei, B.; Khafaie, M.A.; Khajavi, A.; Khalil, I.A.; Khan, E.A.; Khan, M.S.; Khan, M.A.; Khang, Y-H.; Khazaei, M.; Khoja, A.T.; Khosravi, A.; Khosravi, M.H.; Kiadaliri, A.A.; Kiirithio, D.N.; Kim, C-I.; Kim, D.; Kim, P.; Kim, Y-E.; Kim, Y.J.; Kimokoti, R.W.; Kinfu, Y.; Kisa, A.; Kissimova-Skarbek, K.; Kivimäki, M.; Knudsen, A.K.S.; Kocarnik, J.M.; Kochhar, S.; Kokubo, Y.; Kolola, T.; Kopec, J.A.; Kosen, S.; Kotsakis, G.A.; Koul, P.A.; Koyanagi, A.; Kravchenko, M.A.; Krishan, K.; Krohn, K.J.; Kuate, Defo B.; Kucuk Bicer, B.; Kumar, G.A.; Kumar, M.; Kyu, H.H.; Lad, D.P.; Lad, S.D.; Lafranconi, A.; Lalloo, R.; Lallukka, T.; Lami, F.H.; Lansingh, V.C.; Latifi, A.; Lau, K.M-M.; Lazarus, J.V.; Leasher, J.L.; Ledesma, J.R.; Lee, P.H.; Leigh, J.; Leung, J.; Levi, M.; Lewycka, S.; Li, S.; Li, Y.; Liao, Y.; Liben, M.L.; Lim, L-L.; Lim, S.S.; Liu, S.; Lodha, R.; Looker, K.J.; Lopez, A.D.; Lorkowski, S.; Lotufo, P.A.; Low, N.; Lozano, R.; Lucas, T.C.D.; Lucchesi, L.R.; Lunevicius, R.; Lyons, R.A.; Ma, S.; Macarayan, E.R.K.; Mackay, M.T.; Madotto, F.; Magdy Abd El Razek, H.; Magdy Abd El Razek, M.; Maghavani, D.P.; Mahotra, N.B.; Mai, H.T.; Majdan, M.; Majdzadeh, R.; Majeed, A.; Malekzadeh, R.; Malta, D.C.; Mamun, A.A.; Manda, A-L.; Manguerra, H.; Manhertz, T.; Mansournia, M.A.; Mantovani, L.G.; Mapoma, C.C.; Maravilla, J.C.; Marcenes, W.; Marks, A.; Martins-Melo, F.R.; Martopullo, I.; März, W.; Marzan, M.B.; Mashamba-Thompson, T.P.; Massenburg, B.B.; Mathur, M.R.; Matsushita, K.; Maulik, P.K.; Mazidi, M.; McAlinden, C.; McGrath, J.J.; McKee, M.; Mehndiratta, M.M.; Mehrotra, R.; Mehta, K.M.; Mehta, V.; Mejia-Rodriguez, F.; Mekonen, T.; Melese, A.; Melku, M.; Meltzer, M.; Memiah, P.T.N.; Memish, Z.A.; Mendoza, W.; Mengistu, D.T.; Mengistu, G.; Mensah, G.A.; Mereta, S.T.; Meretoja, A.; Meretoja, T.J.; Mestrovic, T.; Mezerji, N.M.G.; Miazgowski, B.; Miazgowski, T.; Millear, A.I.; Miller, T.R.; Miltz, B.; Mini, G.K.; Mirarefin, M.; Mirrakhimov, E.M.; Misganaw, A.T.; Mitchell, P.B.; Mitiku, H.; Moazen, B.; Mohajer, B.; Mohammad, K.A.; Mohammadifard, N.; Mohammadnia-Afrouzi, M.; Mohammed, M.A.; Mohammed, S.; Mohebi, F.; Moitra, M.; Mokdad, A.H.; Molokhia, M.; Monasta, L.; Moodley, Y.; Moosazadeh, M.; Moradi, G.; Moradi-Lakeh, M.; Moradinazar, M.; Moraga, P.; Morawska, L.; Moreno Velásquez, I.; Morgado-Da-Costa, J.; Morrison, S.D.; Moschos, M.M.; Mountjoy-Venning, W.C.; Mousavi, S.M.; Mruts, K.B.; Muche, A.A.; Muchie, K.F.; Mueller, U.O.; Muhammed, O.S.; Mukhopadhyay, S.; Muller, K.; Mumford, J.E.; Murhekar, M.; Musa, J.; Musa, K.I.; Mustafa, G.; Nabhan, A.F.; Nagata, C.; Naghavi, M.; Naheed, A.; Nahvijou, A.; Naik, G.; Naik, N.; Najafi, F.; Naldi, L.; Nam, H.S.; Nangia, V.; Nansseu, J.R.; Nascimento, B.R.; Natarajan, G.; Neamati, N.; Negoi, I.; Negoi, R.I.; Neupane, S.; Newton, C.R.J.; Ngunjiri, J.W.; Nguyen, A.Q.; Nguyen, H.T.; Nguyen, H.L.T.; Nguyen, H.T.; Nguyen, L.H.; Nguyen, M.; Nguyen, N.B.; Nguyen, S.H.; Nichols, E.; Ningrum, D.N.A.; Nixon, M.R.; Nolutshungu, N.; Nomura, S.; Norheim, O.F.; Noroozi, M.; Norrving, B.; Noubiap, J.J.; Nouri, H.R.; Nourollahpour Shiadeh, M.; Nowroozi, M.R.; Nsoesie, E.O.; Nyasulu, P.S.; Odell, C.M.; Ofori-Asenso, R.; Ogbo, F.A.; Oh, I-H.; Oladimeji, O.; Olagunju, A.T.; Olagunju, T.O.; Olivares, P.R.; Olsen, H.E.; Olusanya, B.O.; Ong, K.L.; Ong, S.K.; Oren, E.; Ortiz, A.; Ota, E.; Otstavnov, S.S.; Øverland, S.; Owolabi, M.O.; P A, M.; Pacella, R.; Pakpour, A.H.; Pana, A.; Panda-Jonas, S.; Parisi, A.; Park, E-K.; Parry, C.D.H.; Patel, S.; Pati, S.; Patil, S.T.; Patle, A.; Patton, G.C.; Paturi, V.R.; Paulson, K.R.; Pearce, N.; Pereira, D.M.; Perico, N.; Pesudovs, K.; Pham, H.Q.; Phillips, M.R.; Pigott, D.M.; Pillay, J.D.; Piradov, M.A.; Pirsaheb, M.; Pishgar, F.; Plana-Ripoll, O.; Plass, D.; Polinder, S.; Popova, S.; Postma, M.J.; Pourshams, A.; Poustchi, H.; Prabhakaran, D.; Prakash, S.; Prakash, V.; Purcell, C.A.; Purwar, M.B.; Qorbani, M.; Quistberg, D.A.; Radfar, A.; Rafay, A.; Rafiei, A.; Rahim, F.; Rahimi, K.; Rahimi-Movaghar, A.; Rahimi-Movaghar, V.; Rahman, M.; Rahman, M.H.; Rahman, M.A.; Rahman, S.U.; Rai, R.K.; Rajati, F.; Ram, U.; Ranjan, P.; Ranta, A.; Rao, P.C.; Rawaf, D.L.; Rawaf, S.; Reddy, K.S.; Reiner, R.C.; Reinig, N.; Reitsma, M.B.; Remuzzi, G.; Renzaho, A.M.N.; Resnikoff, S.; Rezaei, S.; Rezai, M.S.; Ribeiro, A.L.P.; Roberts, N.L.S.; Robinson, S.R.; Roever, L.; Ronfani, L.; Roshandel, G.; Rostami, A.; Roth, G.A.; Roy, A.; Rubagotti, E.; Sachdev, P.S.; Sadat, N.; Saddik, B.; Sadeghi, E.; Saeedi Moghaddam, S.; Safari, H.; Safari, Y.; Safari-Faramani, R.; Safdarian, M.; Safi, S.; Safiri, S.; Sagar, R.; Sahebkar, A.; Sahraian, M.A.; Sajadi, H.S.; Salam, N.; Salama, J.S.; Salamati, P.; Saleem, K.; Saleem, Z.; Salimi, Y.; Salomon, J.A.; Salvi, S.S.; Salz, I.; Samy, A.M.; Sanabria, J.; Sang, Y.; Santomauro, D.F.; Santos, I.S.; Santos, J.V.; Santric Milicevic, M.M.; Sao Jose, B.P.; Sardana, M.; Sarker, A.R.; Sarrafzadegan, N.; Sartorius, B.; Sarvi, S.; Sathian, B.; Satpathy, M.; Sawant, A.R.; Sawhney, M.; Saxena, S.; Saylan, M.; Schaeffner, E.; Schmidt, M.I.; Schneider, I.J.C.; Schöttker, B.; Schwebel, D.C.; Schwendicke, F.; Scott, J.G.; Sekerija, M.; Sepanlou, S.G.; Serván-Mori, E.; Seyedmousavi, S.; Shabaninejad, H.; Shafieesabet, A.; Shahbazi, M.; Shaheen, A.A.; Shaikh, M.A.; Shams-Beyranvand, M.; Shamsi, M.; Shamsizadeh, M.; Sharafi, H.; Sharafi, K.; Sharif, M.; Sharif-Alhoseini, M.; Sharma, M.; Sharma, R.; She, J.; Sheikh, A.; Shi, P.; Shibuya, K.; Shigematsu, M.; Shiri, R.; Shirkoohi, R.; Shishani, K.; Shiue, I.; Shokraneh, F.; Shoman, H.; Shrime, M.G.; Si, S.; Siabani, S.; Siddiqi, T.J.; Sigfusdottir, I.D.; Sigurvinsdottir, R.; Silva, J.P.; Silveira, D.G.A.; Singam, N.S.V.; Singh, J.A.; Singh, N.P.; Singh, V.; Sinha, D.N.; Skiadaresi, E.; Slepak, E.L.N.; Sliwa, K.; Smith, D.L.; Smith, M.; Soares Filho, A.M.; Sobaih, B.H.; Sobhani, S.; Sobngwi, E.; Soneji, S.S.; Soofi, M.; Soosaraei, M.; Sorensen, R.J.D.; Soriano, J.B.; Soyiri, I.N.; Sposato, L.A.; Sreeramareddy, C.T.; Srinivasan, V.; Stanaway, J.D.; Stein, D.J.; Steiner, C.; Steiner, T.J.; Stokes, M.A.; Stovner, L.J.; Subart, M.L.; Sudaryanto, A.; Sufiyan, M.B.; Sunguya, B.F.; Sur, P.J.; Sutradhar, I.; Sykes, B.L.; Sylte, D.O.; Tabarés-Seisdedos, R.; Tadakamadla, S.K.; Tadesse, B.T.; Tandon, N.; Tassew, S.G.; Tavakkoli, M.; Taveira, N.; Taylor, H.R.; Tehrani-Banihashemi, A.; Tekalign, T.G.; Tekelemedhin, S.W.; Tekle, M.G.; Temesgen, H.; Temsah, M-H.; Temsah, O.; Terkawi, A.S.; Teweldemedhin, M.; Thankappan, K.R.; Thomas, N.; Tilahun, B.; To, Q.G.; Tonelli, M.; Topor-Madry, R.; Topouzis, F.; Torre, A.E.; Tortajada-Girbés, M.; Touvier, M.; Tovani-Palone, M.R.; Towbin, J.A.; Tran, B.X.; Tran, K.B.; Troeger, C.E.; Truelsen, T.C.; Tsilimbaris, M.K.; Tsoi, D.; Tudor Car, L.; Tuzcu, E.M.; Ukwaja, K.N.; Ullah, I.; Undurraga, E.A.; Unutzer, J.; Updike, R.L.; Usman, M.S.; Uthman, O.A.; Vaduganathan, M.; Vaezi, A.; Valdez, P.R.; Varughese, S.; Vasankari, T.J.; Venketasubramanian, N.; Villafaina, S.; Violante, F.S.; Vladimirov, S.K.; Vlassov, V.; Vollset, S.E.; Vosoughi, K.; Vujcic, I.S.; Wagnew, F.S.; Waheed, Y.; Waller, S.G.; Wang, Y.; Wang, Y-P.; Weiderpass, E.; Weintraub, R.G.; Weiss, D.J.; Weldegebreal, F.; Weldegwergs, K.G.; Werdecker, A.; West, T.E.; Whiteford, H.A.; Widecka, J.; Wijeratne, T.; Wilner, L.B.; Wilson, S.; Winkler, A.S.; Wiyeh, A.B.; Wiysonge, C.S.; Wolfe, C.D.A.; Woolf, A.D.; Wu, S.; Wu, Y-C.; Wyper, G.M.A.; Xavier, D.; Xu, G.; Yadgir, S.; Yadollahpour, A.; Yahyazadeh Jabbari, S.H.; Yamada, T.; Yan, L.L.; Yano, Y.; Yaseri, M.; Yasin, Y.J.; Yeshaneh, A.; Yimer, E.M.; Yip, P.; Yisma, E.; Yonemoto, N.; Yoon, S-J.; Yotebieng, M.; Younis, M.Z.; Yousefifard, M.; Yu, C.; Zadnik, V.; Zaidi, Z.; Zaman, S.B.; Zamani, M.; Zare, Z.; Zeleke, A.J.; Zenebe, Z.M.; Zhang, K.; Zhao, Z.; Zhou, M.; Zodpey, S.; Zucker, I.; Vos, T.; Murray, C.J.L. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, 2018, 392(10159), 1789-1858. doi: 10.1016/S0140-6736(18)32279-7 PMID: 30496104
  3. GBD 2017: a fragile world. Lancet, 2018, 392(10159), 1683. doi: 10.1016/S0140-6736(18)32858-7 PMID: 30415747
  4. Santomauro, D.F.; Mantilla, H.A.M.; Shadid, J.; Zheng, P.; Ashbaugh, C.; Pigott, D.M.; Abbafati, C.; Adolph, C.; Amlag, J.O.; Aravkin, A.Y.; Bang-Jensen, B.L.; Bertolacci, G.J.; Bloom, S.S.; Castellano, R.; Castro, E.; Chakrabarti, S.; Chattopadhyay, J.; Cogen, R.M.; Collins, J.K.; Dai, X.; Dangel, W.J.; Dapper, C.; Deen, A.; Erickson, M.; Ewald, S.B.; Flaxman, A.D.; Frostad, J.J.; Fullman, N.; Giles, J.R.; Giref, A.Z.; Guo, G.; He, J.; Helak, M.; Hulland, E.N.; Idrisov, B.; Lindstrom, A.; Linebarger, E.; Lotufo, P.A.; Lozano, R.; Magistro, B.; Malta, D.C.; Månsson, J.C.; Marinho, F.; Mokdad, A.H.; Monasta, L.; Naik, P.; Nomura, S.; O’Halloran, J.K.; Ostroff, S.M.; Pasovic, M.; Penberthy, L.; Reiner, R.C., Jr; Reinke, G.; Ribeiro, A.L.P.; Sholokhov, A.; Sorensen, R.J.D.; Varavikova, E.; Vo, A.T.; Walcott, R.; Watson, S.; Wiysonge, C.S.; Zigler, B.; Hay, S.I.; Vos, T.; Murray, C.J.L.; Whiteford, H.A.; Ferrari, A.J. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet, 2021, 398(10312), 1700-1712. doi: 10.1016/S0140-6736(21)02143-7 PMID: 34634250
  5. Malhi, G.S.; Mann, J.J. Depression. Lancet, 2018, 392(10161), 2299-2312. doi: 10.1016/S0140-6736(18)31948-2 PMID: 30396512
  6. Beurel, E.; Toups, M.; Nemeroff, C.B. The bidirectional relationship of depression and inflammation: Double trouble. Neuron, 2020, 107(2), 234-256. doi: 10.1016/j.neuron.2020.06.002 PMID: 32553197
  7. Gartlehner, G.; Wagner, G.; Matyas, N.; Titscher, V.; Greimel, J.; Lux, L.; Gaynes, B.N.; Viswanathan, M.; Patel, S.; Lohr, K.N. Pharmacological and non-pharmacological treatments for major depressive disorder: review of systematic reviews. BMJ Open, 2017, 7(6), e014912. doi: 10.1136/bmjopen-2016-014912 PMID: 28615268
  8. Schildkraut, J.J. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am. J. Psychiatry, 1965, 122(5), 509-522. doi: 10.1176/ajp.122.5.509 PMID: 5319766
  9. Dale, E.; Bang-Andersen, B.; Sánchez, C. Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs. Biochem. Pharmacol., 2015, 95(2), 81-97. doi: 10.1016/j.bcp.2015.03.011 PMID: 25813654
  10. Stahl, S.M. Mood Disorders and Antidepressants: Stahl’s Essential Psychopharmacology; Cambridge university press, 2013.
  11. Rush, A.J.; Trivedi, M.H.; Wisniewski, S.R.; Nierenberg, A.A.; Stewart, J.W.; Warden, D.; Niederehe, G.; Thase, M.E.; Lavori, P.W.; Lebowitz, B.D.; McGrath, P.J.; Rosenbaum, J.F.; Sackeim, H.A.; Kupfer, D.J.; Luther, J.; Fava, M. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry, 2006, 163(11), 1905-1917. doi: 10.1176/ajp.2006.163.11.1905 PMID: 17074942
  12. Su, W.J.; Cao, Z.Y.; Jiang, C.L. Blocking the trigger: An integrative view on the anti-inflammatory therapy of depression. Brain Behav. Immun., 2019, 82, 10-12. doi: 10.1016/j.bbi.2019.09.002 PMID: 31493446
  13. Gartlehner, G.; Thieda, P.; Hansen, R.A.; Gaynes, B.N.; DeVeaugh-Geiss, A.; Krebs, E.E.; Lohr, K.N. Comparative risk for harms of second-generation antidepressants: A systematic review and meta-analysis. Drug Saf., 2008, 31(10), 851-865. doi: 10.2165/00002018-200831100-00004 PMID: 18759509
  14. Ogłodek, E.; Szota, A.; Just, M.; Moś D.; Araszkiewicz, A. The role of the neuroendocrine and immune systems in the pathogenesis of depression. Pharmacol. Rep., 2014, 66(5), 776-781. doi: 10.1016/j.pharep.2014.04.009 PMID: 25149980
  15. Numakawa, T.; Richards, M.; Nakajima, S.; Adachi, N.; Furuta, M.; Odaka, H.; Kunugi, H. The role of brain-derived neurotrophic factor in comorbid depression: possible linkage with steroid hormones, cytokines, and nutrition. Front. Psychiatry, 2014, 5, 136. doi: 10.3389/fpsyt.2014.00136 PMID: 25309465
  16. Verduijn, J.; Milaneschi, Y.; Schoevers, R.A.; van Hemert, A.M.; Beekman, A.T.F.; Penninx, B.W.J.H. Pathophysiology of major depressive disorder: mechanisms involved in etiology are not associated with clinical progression. Transl. Psychiatry, 2015, 5(9), e649. doi: 10.1038/tp.2015.137 PMID: 26418277
  17. Koo, J.W.; Wohleb, E.S. How stress shapes neuroimmune function: Implications for the neurobiology of psychiatric disorders. Biol. Psychiatry, 2021, 90(2), 74-84. doi: 10.1016/j.biopsych.2020.11.007 PMID: 33485589
  18. Ishikawa, Y.; Furuyashiki, T. The impact of stress on immune systems and its relevance to mental illness. Neurosci. Res., 2022, 175, 16-24. doi: 10.1016/j.neures.2021.09.005 PMID: 34606943
  19. Tafet, G.E.; Nemeroff, C.B. The links between stress and depression: Psychoneuroendocrinological, genetic, and environmental interactions. J. Neuropsychiatry Clin. Neurosci., 2016, 28(2), 77-88. doi: 10.1176/appi.neuropsych.15030053 PMID: 26548654
  20. Smith, R.S. The macrophage theory of depression. Med. Hypotheses, 1991, 35(4), 298-306. doi: 10.1016/0306-9877(91)90272-Z PMID: 1943879
  21. Pape, K.; Tamouza, R.; Leboyer, M.; Zipp, F. Immunoneuropsychiatry — novel perspectives on brain disorders. Nat. Rev. Neurol., 2019, 15(6), 317-328. doi: 10.1038/s41582-019-0174-4 PMID: 30988501
  22. Carlsson, A.; Corrodi, H.; Fuxe, K.; Hökfelt, T. Effect of antidepressant drugs on the depletion of intraneuronal brain 5-hydroxytryptamine stores caused by 4-methyl-α-ethyl-meta-tyramine. Eur. J. Pharmacol., 1969, 5(4), 357-366. doi: 10.1016/0014-2999(69)90113-7 PMID: 5786359
  23. Cipriani, A.; Furukawa, T.A.; Salanti, G.; Chaimani, A.; Atkinson, L.Z.; Ogawa, Y.; Leucht, S.; Ruhe, H.G.; Turner, E.H.; Higgins, J.P.T.; Egger, M.; Takeshima, N.; Hayasaka, Y.; Imai, H.; Shinohara, K.; Tajika, A.; Ioannidis, J.P.A.; Geddes, J.R. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis. Lancet, 2018, 391(10128), 1357-1366. doi: 10.1016/S0140-6736(17)32802-7 PMID: 29477251
  24. Wetsman, N. Inflammatory illness: Why the next wave of antidepressants may target the immune system. Nat. Med., 2017, 23(9), 1009-1011. doi: 10.1038/nm0917-1009 PMID: 28886000
  25. Hamidpour, R.; Hamidpour, S.; Hamidpour, M.; Shahlari, M. Frankincense (rǔ xiāng; boswellia species): from the selection of traditional applications to the novel phytotherapy for the prevention and treatment of serious diseases. J. Tradit. Complement. Med., 2013, 3(4), 221-226. doi: 10.4103/2225-4110.119723 PMID: 24716181
  26. Yao, G.; Li, J.; Wang, J.; Liu, S.; Li, X.; Cao, X.; Chen, H.; Xu, Y. Improved resting-state functional dynamics in post-stroke depressive patients after shugan jieyu capsule treatment. Front. Neurosci., 2020, 14, 297. doi: 10.3389/fnins.2020.00297 PMID: 32372901
  27. Tan, J.; Li, X.; Zhu, Y.; Sullivan, M.A.; Deng, B.; Zhai, X.; Lu, Y. Antidepressant shugan jieyu capsule alters gut microbiota and intestinal microbiome function in rats with chronic unpredictable mild stress -induced depression. Front. Pharmacol., 2022, 13, 828595. doi: 10.3389/fphar.2022.828595 PMID: 35770090
  28. Miller, J. Antidepressants, part 1: 100 years and counting. Psychiatr. Times, 2017, 34(10), 23-26.
  29. Shitiz, K.; Gupta, S.P. Rauwolfia serpentina; Himalayan Medicinal Plants, 2021. doi: 10.1016/B978-0-12-823151-7.00009-X
  30. Vakil, R.J. Rauwolfia serpentina in the treatment of high blood pressure; a review of the literature. Circulation, 1955, 12(2), 220-229. doi: 10.1161/01.CIR.12.2.220 PMID: 13240803
  31. Quetsch, R.M.; Achor, R.W.P.; Litin, E.M.; Faucett, R.L. Depressive reactions in hypertensive patients; a comparison of those treated with Rauwolfia and those receiving no specific antihypertensive treatment. Circulation, 1959, 19(3), 366-375. doi: 10.1161/01.CIR.19.3.366 PMID: 13629798
  32. Robitzek, E.H.; Selikoff, I.J. Hydrazine derivatives of isonicotinic acid (rimifon marsilid) in the treatment of active progressive caseous-pneumonic tuberculosis; a preliminary report. Am. Rev. Tuberc., 1952, 65(4), 402-428. PMID: 14903507
  33. Brown, W.A.; Rosdolsky, M. The clinical discovery of imipramine. Am. J. Psychiatry, 2015, 172(5), 426-429. doi: 10.1176/appi.ajp.2015.14101336 PMID: 25930134
  34. Axelrod, J.; Whitby, L.G.; Hertting, G. Effect of psychotropic drugs on the uptake of H3-norepinephrine by tissues. Science, 1961, 133(3450), 383-384. doi: 10.1126/science.133.3450.383 PMID: 13685337
  35. Fleming, A.; Eisendrath, S. Depression. In: Encyclopedia of the Neurological Sciences; Aminoff, M.J.; Daroff, R.B., Eds.; Academic Press: New York, 2003; pp. 853-860. doi: 10.1016/B0-12-226870-9/01067-4
  36. Harmer, C.J.; Duman, R.S.; Cowen, P.J. How do antidepressants work? New perspectives for refining future treatment approaches. Lancet Psychiatry, 2017, 4(5), 409-418. doi: 10.1016/S2215-0366(17)30015-9 PMID: 28153641
  37. Bauer, M.; Bschor, T.; Pfennig, A.; Whybrow, P.C.; Angst, J.; Versiani, M.; Möller, H.J.; Bauer, M.; Bschor, T.; Pfennig, A.; Whybrow, P.C.; Angst, J.; Versiani, M.; Möller, H-J. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care. World J. Biol. Psychiatry, 2007, 8(2), 67-104. doi: 10.1080/15622970701227829 PMID: 17455102
  38. Cleare, A.; Pariante, C.M.; Young, A.H.; Anderson, I.M.; Christmas, D.; Cowen, P.J.; Dickens, C.; Ferrier, I.N.; Geddes, J.; Gilbody, S.; Haddad, P.M.; Katona, C.; Lewis, G.; Malizia, A.; McAllister-Williams, R.H.; Ramchandani, P.; Scott, J.; Taylor, D.; Uher, R. Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. J. Psychopharmacol., 2015, 29(5), 459-525. doi: 10.1177/0269881115581093 PMID: 25969470
  39. Deardorff, W.J.; Grossberg, G.T. A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine. Expert Opin. Pharmacother., 2014, 15(17), 2525-2542. doi: 10.1517/14656566.2014.960842 PMID: 25224953
  40. Kent, J.M. SNaRIs, NaSSAs, and NaRIs: New agents for the treatment of depression. Lancet, 2000, 355(9207), 911-918. doi: 10.1016/S0140-6736(99)11381-3 PMID: 10752718
  41. Guaiana, G.; Gupta, S.; Chiodo, D.; Davies, S.J.C.; Haederle, K.; Koesters, M. Agomelatine versus other antidepressive agents for major depression. Cochrane Libr., 2013, (12), CD008851. doi: 10.1002/14651858.CD008851.pub2 PMID: 24343836
  42. Taylor, D.; Sparshatt, A.; Varma, S.; Olofinjana, O. Antidepressant efficacy of agomelatine: Meta-analysis of published and unpublished studies. BMJ, 2014, 348, g1888. doi: 10.1136/bmj.g1888
  43. Berman, R.M.; Cappiello, A.; Anand, A.; Oren, D.A.; Heninger, G.R.; Charney, D.S.; Krystal, J.H. Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry, 2000, 47(4), 351-354. doi: 10.1016/S0006-3223(99)00230-9 PMID: 10686270
  44. Ramadan, A.M.; Mansour, I.A. Could ketamine be the answer to treating treatment-resistant major depressive disorder? Gen. Psychiatr., 2020, 33(5), e100227. doi: 10.1136/gpsych-2020-100227 PMID: 32875273
  45. Mcdonald, E.M.; Mann, A.H.; Thomas, H.C. Interferons as mediators of psychiatric morbidity. An investigation in a trial of recombinant alpha-interferon in hepatitis-B carriers. Lancet, 1987, 330(8569), 1175-1178. doi: 10.1016/S0140-6736(87)91319-5 PMID: 2890808
  46. Niiranen, A.; Laaksonen, R. livanainen, M.; Mattson, K.; Färkkilä, M.; Cantell, K. Behavioral assessment of patients treated with alpha-interferon. Acta Psychiatr. Scand., 1988, 78(5), 622-626. doi: 10.1111/j.1600-0447.1988.tb06395.x PMID: 3232542
  47. Maes, M.; Smith, R.; Simon, S. The monocyte-T-lymphocyte hypothesis of major depression. Psychoneuroendocrinology, 1995, 20(2), 111-116. doi: 10.1016/0306-4530(94)00066-J PMID: 7899532
  48. Dantzer, R.; O’Connor, J.C.; Freund, G.G.; Johnson, R.W.; Kelley, K.W. From inflammation to sickness and depression: When the immune system subjugates the brain. Nat. Rev. Neurosci., 2008, 9(1), 46-56. doi: 10.1038/nrn2297 PMID: 18073775
  49. Kim, Y.K.; Na, K.S.; Myint, A.M.; Leonard, B.E. The role of pro-inflammatory cytokines in neuroinflammation, neurogenesis and the neuroendocrine system in major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2016, 64, 277-284. doi: 10.1016/j.pnpbp.2015.06.008 PMID: 26111720
  50. Petralia, M.C.; Mazzon, E.; Fagone, P.; Basile, M.S.; Lenzo, V.; Quattropani, M.C.; Di Nuovo, S.; Bendtzen, K.; Nicoletti, F. The cytokine network in the pathogenesis of major depressive disorder. Close to translation? Autoimmun. Rev., 2020, 19(5), 102504. doi: 10.1016/j.autrev.2020.102504 PMID: 32173514
  51. Raison, C.L.; Capuron, L.; Miller, A.H. Cytokines sing the blues: Inflammation and the pathogenesis of depression. Trends Immunol., 2006, 27(1), 24-31. doi: 10.1016/j.it.2005.11.006 PMID: 16316783
  52. Su, W.J.; Cao, Z.Y.; Jiang, C.L. Inflammatory mechanism of depression and its new strategy for diagnosis and treatment. Sheng Li Xue Bao, 2017, 69(5), 715-722. PMID: 29063119
  53. Young, J.J.; Bruno, D.; Pomara, N. A review of the relationship between proinflammatory cytokines and major depressive disorder. J. Affect. Disord., 2014, 169, 15-20. doi: 10.1016/j.jad.2014.07.032 PMID: 25128861
  54. Howren, M.B.; Lamkin, D.M.; Suls, J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom. Med., 2009, 71(2), 171-186. doi: 10.1097/PSY.0b013e3181907c1b PMID: 19188531
  55. Dowlati, Y.; Herrmann, N.; Swardfager, W.; Liu, H.; Sham, L.; Reim, E.K.; Lanctôt, K.L. A meta-analysis of cytokines in major depression. Biol. Psychiatry, 2010, 67(5), 446-457. doi: 10.1016/j.biopsych.2009.09.033 PMID: 20015486
  56. Köhler, C.A.; Freitas, T.H.; Maes, M.; de Andrade, N.Q.; Liu, C.S.; Fernandes, B.S.; Stubbs, B.; Solmi, M.; Veronese, N.; Herrmann, N.; Raison, C.L.; Miller, B.J.; Lanctôt, K.L.; Carvalho, A.F. Peripheral cytokine and chemokine alterations in depression: A meta-analysis of 82 studies. Acta Psychiatr. Scand., 2017, 135(5), 373-387. doi: 10.1111/acps.12698 PMID: 28122130
  57. Enache, D.; Pariante, C.M.; Mondelli, V. Markers of central inflammation in major depressive disorder: A systematic review and meta-analysis of studies examining cerebrospinal fluid, positron emission tomography and post-mortem brain tissue. Brain Behav. Immun., 2019, 81, 24-40. doi: 10.1016/j.bbi.2019.06.015 PMID: 31195092
  58. Matcham, F.; Rayner, L.; Steer, S.; Hotopf, M. The prevalence of depression in rheumatoid arthritis: A systematic review and meta-analysis. Rheumatology, 2013, 52(12), 2136-2148. doi: 10.1093/rheumatology/ket169 PMID: 24003249
  59. Barberio, B.; Zamani, M.; Black, C.J.; Savarino, E.V.; Ford, A.C. Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: A systematic review and meta-analysis. Lancet Gastroenterol. Hepatol., 2021, 6(5), 359-370. doi: 10.1016/S2468-1253(21)00014-5 PMID: 33721557
  60. Dowlatshahi, E.A.; Wakkee, M.; Arends, L.R.; Nijsten, T. The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: A systematic review and meta-analysis. J. Invest. Dermatol., 2014, 134(6), 1542-1551. doi: 10.1038/jid.2013.508 PMID: 24284419
  61. Moustafa, A.T.; Moazzami, M.; Engel, L.; Bangert, E.; Hassanein, M.; Marzouk, S.; Kravtsenyuk, M.; Fung, W.; Eder, L.; Su, J.; Wither, J.E.; Touma, Z. Prevalence and metric of depression and anxiety in systemic lupus erythematosus: A systematic review and meta-analysis. Semin. Arthritis Rheum., 2020, 50(1), 84-94. doi: 10.1016/j.semarthrit.2019.06.017 PMID: 31303437
  62. Fotopoulos, A.; Petrikis, P.; Sioka, C. Depression and coronary artery disease. Psychiatr. Danub., 2021, 33(1), 73. PMID: 33857047
  63. McFarland, D.C.; Doherty, M.; Atkinson, T.M.; O’Hanlon, R.; Breitbart, W.; Nelson, C.J.; Miller, A.H. Cancer‐related inflammation and depressive symptoms: Systematic review and meta‐analysis. Cancer, 2022, 128(13), 2504-2519. doi: 10.1002/cncr.34193 PMID: 35417925
  64. Gold, S.M.; Köhler-Forsberg, O.; Moss-Morris, R.; Mehnert, A.; Miranda, J.J.; Bullinger, M.; Steptoe, A.; Whooley, M.A.; Otte, C. Comorbid depression in medical diseases. Nat. Rev. Dis. Primers, 2020, 6(1), 69. doi: 10.1038/s41572-020-0200-2 PMID: 32820163
  65. Schaefer, M.; Engelbrechta, M.A.; Gut, O.; Fiebich, B.L.; Bauer, J.; Schmidt, F.; Grunze, H.; Lieb, K. Interferon alpha (IFNα) and psychiatric syndromes. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2002, 26(4), 731-746. doi: 10.1016/S0278-5846(01)00324-4 PMID: 12188106
  66. Benson, S.; Engler, H.; Wegner, A.; Rebernik, L.; Spreitzer, I.; Schedlowski, M.; Elsenbruch, S. What makes you feel sick after inflammation? predictors of acute and persisting physical sickness symptoms induced by experimental endotoxemia. Clin. Pharmacol. Ther., 2017, 102(1), 141-151. doi: 10.1002/cpt.618 PMID: 28074475
  67. Kim, Y.K.; Na, K.S.; Shin, K.H.; Jung, H.Y.; Choi, S.H.; Kim, J.B. Cytokine imbalance in the pathophysiology of major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2007, 31(5), 1044-1053. doi: 10.1016/j.pnpbp.2007.03.004 PMID: 17433516
  68. Wu, H.; Denna, T.H.; Storkersen, J.N.; Gerriets, V.A. Beyond a neurotransmitter: The role of serotonin in inflammation and immunity. Pharmacol. Res., 2019, 140, 100-114. doi: 10.1016/j.phrs.2018.06.015 PMID: 29953943
  69. Wang, L.; Wang, R.; Liu, L.; Qiao, D.; Baldwin, D.S.; Hou, R. Effects of SSRIs on peripheral inflammatory markers in patients with major depressive disorder: A systematic review and meta-analysis. Brain Behav. Immun., 2019, 79, 24-38. doi: 10.1016/j.bbi.2019.02.021 PMID: 30797959
  70. Dionisie, V.; Filip, G.A.; Manea, M.C.; Manea, M.; Riga, S. The anti-inflammatory role of SSRI and SNRI in the treatment of depression: a review of human and rodent research studies. Inflammopharmacology, 2021, 29(1), 75-90. doi: 10.1007/s10787-020-00777-5 PMID: 33164143
  71. O’Brien, S.M.; Scully, P.; Fitzgerald, P.; Scott, L.V.; Dinan, T.G. Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J. Psychiatr. Res., 2007, 41(3-4), 326-331. doi: 10.1016/j.jpsychires.2006.05.013 PMID: 16870211
  72. Strawbridge, R.; Marwood, L.; King, S.; Young, A.H.; Pariante, C.M.; Colasanti, A.; Cleare, A.J. Inflammatory proteins and clinical response to psychological therapy in patients with depression: An exploratory study. J. Clin. Med., 2020, 9(12), 3918. doi: 10.3390/jcm9123918 PMID: 33276697
  73. Suarez, E.C.; Krishnan, R.R.; Lewis, J.G. The relation of severity of depressive symptoms to monocyte-associated proinflammatory cytokines and chemokines in apparently healthy men. Psychosom. Med., 2003, 65(3), 362-368. doi: 10.1097/01.PSY.0000035719.79068.2B PMID: 12764208
  74. Kappelmann, N.; Lewis, G.; Dantzer, R.; Jones, P.B.; Khandaker, G.M. Antidepressant activity of anti-cytokine treatment: A systematic review and meta-analysis of clinical trials of chronic inflammatory conditions. Mol. Psychiatry, 2018, 23(2), 335-343. doi: 10.1038/mp.2016.167 PMID: 27752078
  75. Rethorst, C.D.; Toups, M.S.; Greer, T.L.; Nakonezny, P.A.; Carmody, T.J.; Grannemann, B.D.; Huebinger, R.M.; Barber, R.C.; Trivedi, M.H. Pro-inflammatory cytokines as predictors of antidepressant effects of exercise in major depressive disorder. Mol. Psychiatry, 2013, 18(10), 1119-1124. doi: 10.1038/mp.2012.125 PMID: 22925832
  76. O’Donovan, A.; Rush, G.; Hoatam, G.; Hughes, B.M.; McCrohan, A.; Kelleher, C.; O’Farrelly, C.; Malone, K.M. Suicidal ideation is associated with elevated inflammation in patients with major depressive disorder. Depress. Anxiety, 2013, 30(4), 307-314. doi: 10.1002/da.22087 PMID: 23504697
  77. Black, C.; Miller, B.J. Meta-analysis of cytokines and chemokines in suicidality: Distinguishing suicidal versus nonsuicidal patients. Biol. Psychiatry, 2015, 78(1), 28-37. doi: 10.1016/j.biopsych.2014.10.014 PMID: 25541493
  78. Fazel, S.; Runeson, B. Suicide. N. Engl. J. Med., 2020, 382(3), 266-274. doi: 10.1056/NEJMra1902944 PMID: 31940700
  79. Yan, W.J.; Jiang, C.L.; Su, W.J. Life in the flame: Inflammation sounds the alarm for suicide risk. Brain, Behavior, & Immunity - Health, 2021, 14, 100250. doi: 10.1016/j.bbih.2021.100250 PMID: 34589761
  80. Franklin, T.C.; Xu, C.; Duman, R.S. Depression and sterile inflammation: Essential role of danger associated molecular patterns. Brain Behav. Immun., 2018, 72, 2-13. doi: 10.1016/j.bbi.2017.10.025 PMID: 29102801
  81. Chen, G.Y.; Nuñez, G. Sterile inflammation: Sensing and reacting to damage. Nat. Rev. Immunol., 2010, 10(12), 826-837. doi: 10.1038/nri2873 PMID: 21088683
  82. Perrin, A.J.; Horowitz, M.A.; Roelofs, J.; Zunszain, P.A.; Pariante, C.M. Glucocorticoid resistance: Is it a requisite for increased cytokine production in depression? a systematic review and meta-analysis. Front. Psychiatry, 2019, 10, 423. doi: 10.3389/fpsyt.2019.00423 PMID: 31316402
  83. Chen, S.; Zhang, Y.; Yuan, Y. The combination of serum BDNF, cortisol and IFN-gamma can assist the diagnosis of major depressive disorder. Neuropsychiatr. Dis. Treat., 2021, 17, 2819-2829. doi: 10.2147/NDT.S322078 PMID: 34471356
  84. Amasi-Hartoonian, N.; Sforzini, L.; Cattaneo, A.; Pariante, C.M. Cause or consequence? Understanding the role of cortisol in the increased inflammation observed in depression. Curr. Opin. Endocr. Metab. Res., 2022, 24, 100356. doi: 10.1016/j.coemr.2022.100356 PMID: 35634363
  85. Pace, T.W.W.; Miller, A.H. Cytokines and glucocorticoid receptor signaling. Relevance to major depression. Ann. N. Y. Acad. Sci., 2009, 1179(1), 86-105. doi: 10.1111/j.1749-6632.2009.04984.x PMID: 19906234
  86. Lauer, C.J.; Schreiber, W.; Modell, S.; Holsboer, F.; Krieg, J.C. The Munich vulnerability study on affective disorders: overview of the cross-sectional observations at index investigation. J. Psychiatr. Res., 1998, 32(6), 393-401. doi: 10.1016/S0022-3956(98)00026-0 PMID: 9844956
  87. Kim, Y.K.; Won, E. The influence of stress on neuroinflammation and alterations in brain structure and function in major depressive disorder. Behav. Brain Res., 2017, 329, 6-11. doi: 10.1016/j.bbr.2017.04.020 PMID: 28442354
  88. Maes, M.; Song, C.; Lin, A.; De Jongh, R.; Van Gastel, A.; Kenis, G.; Bosmans, E.; De Meester, I.; Benoy, I.; Neels, H.; Demedts, P.; Janca, A.; Scharpé, S.; Smith, R.S. The effects of psychological stress on humans: increased production of pro-inflammatory cytokines and a Th1-like response in stress-induced anxiety. Cytokine, 1998, 10(4), 313-318. doi: 10.1006/cyto.1997.0290 PMID: 9617578
  89. Mittwoch-Jaffe, T.; Shalit, F.; Srendi, B.; Yehuda, S. Modification of cytokine secretion following mild emotional stimuli. Neuroreport, 1995, 6(5), 789-792. doi: 10.1097/00001756-199503270-00021 PMID: 7605950
  90. Dobbin, J.P.; Harth, M.; McCain, G.A.; Martin, R.A.; Cousin, K. Cytokine production and lymphocyte transformation during stress. Brain Behav. Immun., 1991, 5(4), 339-348. doi: 10.1016/0889-1591(91)90029-A PMID: 1777728
  91. Su, W.J.; Zhang, T.; Jiang, C.L.; Wang, W. Clemastine alleviates depressive-like behavior through reversing the imbalance of microglia-related pro-inflammatory state in mouse hippocampus. Front. Cell. Neurosci., 2018, 12, 412. doi: 10.3389/fncel.2018.00412 PMID: 30483062
  92. Berk, M.; Williams, L.J.; Jacka, F.N.; O’Neil, A.; Pasco, J.A.; Moylan, S.; Allen, N.B.; Stuart, A.L.; Hayley, A.C.; Byrne, M.L.; Maes, M. So depression is an inflammatory disease, but where does the inflammation come from? BMC Med., 2013, 11(1), 200. doi: 10.1186/1741-7015-11-200 PMID: 24228900
  93. Rider, P.; Voronov, E.; Dinarello, C.A.; Apte, R.N.; Cohen, I. Alarmins: Feel the stress. J. Immunol., 2017, 198(4), 1395-1402. doi: 10.4049/jimmunol.1601342 PMID: 28167650
  94. Samir, P.; Kesavardhana, S.; Patmore, D.M.; Gingras, S.; Malireddi, R.K.S.; Karki, R.; Guy, C.S.; Briard, B.; Place, D.E.; Bhattacharya, A.; Sharma, B.R.; Nourse, A.; King, S.V.; Pitre, A.; Burton, A.R.; Pelletier, S.; Gilbertson, R.J.; Kanneganti, T.D. DDX3X acts as a live-or-die checkpoint in stressed cells by regulating NLRP3 inflammasome. Nature, 2019, 573(7775), 590-594. doi: 10.1038/s41586-019-1551-2 PMID: 31511697
  95. Troubat, R.; Barone, P.; Leman, S.; Desmidt, T.; Cressant, A.; Atanasova, B.; Brizard, B.; El Hage, W.; Surget, A.; Belzung, C.; Camus, V. Neuroinflammation and depression: A review. Eur. J. Neurosci., 2021, 53(1), 151-171. doi: 10.1111/ejn.14720 PMID: 32150310
  96. Blatteis, C.M.; Bealer, S.L.; Hunter, W.S.; Llanos, J-Q.; Ahokas, R.A.; Mashburn, T.A., Jr Suppression of fever after lesions of the anteroventral third ventricle in guinea pigs. Brain Res. Bull., 1983, 11(5), 519-526. doi: 10.1016/0361-9230(83)90124-7 PMID: 6365250
  97. Hsuchou, H.; Kastin, A.J.; Mishra, P.K.; Pan, W. C-reactive protein increases BBB permeability: Implications for obesity and neuroinflammation. Cell. Physiol. Biochem., 2012, 30(5), 1109-1119. doi: 10.1159/000343302 PMID: 23018453
  98. Banks, W.A.; Kastin, A.J.; Durham, D.A. Bidirectional transport of interleukin-1 alpha across the blood-brain barrier. Brain Res. Bull., 1989, 23(6), 433-437. doi: 10.1016/0361-9230(89)90185-8 PMID: 2611685
  99. Pan, W.; Kastin, A.J. TNFalpha transport across the blood-brain barrier is abolished in receptor knockout mice. Exp. Neurol., 2002, 174(2), 193-200. doi: 10.1006/exnr.2002.7871 PMID: 11922661
  100. Watkins, L.R.; Goehler, L.E.; Relton, J.K.; Tartaglia, N.; Silbert, L.; Martin, D.; Maier, S.F. Blockade of interleukin-1 induced hyperthermia by subdiaphragmatic vagotomy: Evidence for vagal mediation of immune-brain communication. Neurosci. Lett., 1995, 183(1-2), 27-31. doi: 10.1016/0304-3940(94)11105-R PMID: 7746479
  101. Verma, S.; Nakaoke, R.; Dohgu, S.; Banks, W.A. Release of cytokines by brain endothelial cells: A polarized response to lipopolysaccharide. Brain Behav. Immun., 2006, 20(5), 449-455. doi: 10.1016/j.bbi.2005.10.005 PMID: 16309883
  102. Harry, G.J.; Kraft, A.D. Neuroinflammation and microglia: Considerations and approaches for neurotoxicity assessment. Expert Opin. Drug Metab. Toxicol., 2008, 4(10), 1265-1277. doi: 10.1517/17425255.4.10.1265 PMID: 18798697
  103. D’Mello, C.; Le, T.; Swain, M.G. Cerebral microglia recruit monocytes into the brain in response to tumor necrosis factoralpha signaling during peripheral organ inflammation. J. Neurosci., 2009, 29(7), 2089-2102. doi: 10.1523/JNEUROSCI.3567-08.2009 PMID: 19228962
  104. Peraçoli, M.; Kurokawa, C.S.; Calvi, S.A.; Mendes, R.P.; Pereira, P.C.; Marques, S.A.; Soares, A.M. Production of pro- and anti-inflammatory cytokines by monocytes from patients with paracoccidioidomycosis. Microbes Infect., 2003, 5(5), 413-418. doi: 10.1016/S1286-4579(03)00040-6 PMID: 12737997
  105. Gritti, D.; Delvecchio, G.; Ferro, A.; Bressi, C.; Brambilla, P. Neuroinflammation in major depressive disorder: A review of pet imaging studies examining the 18-kDa translocator protein. J. Affect. Disord., 2021, 292, 642-651. doi: 10.1016/j.jad.2021.06.001 PMID: 34153835
  106. Köhler-Forsberg, O.N.; Lydholm, C.; Hjorthøj, C.; Nordentoft, M.; Mors, O.; Benros, M.E. Efficacy of anti-inflammatory treatment on major depressive disorder or depressive symptoms: Meta-analysis of clinical trials. Acta Psychiatr. Scand., 2019, 139(5), 404-419. doi: 10.1111/acps.13016 PMID: 30834514
  107. Shim, H. One target, different effects: A comparison of distinct therapeutic antibodies against the same targets. Exp. Mol. Med., 2011, 43(10), 539-549. doi: 10.3858/emm.2011.43.10.063 PMID: 21811090
  108. Zhao, S.; Chadwick, L.; Mysler, E.; Moots, R.J. Review of biosimilar trials and data on adalimumab in rheumatoid arthritis. Curr. Rheumatol. Rep., 2018, 20(10), 57. doi: 10.1007/s11926-018-0769-6 PMID: 30094742
  109. Cvetković R.S.; Scott, L.J. Adalimumab: A review of its use in adult patients with rheumatoid arthritis. BioDrugs, 2006, 20(5), 293-311. doi: 10.2165/00063030-200620050-00005 PMID: 17025376
  110. Loftus, E.V.; Feagan, B.G.; Colombel, J.F.; Rubin, D.T.; Wu, E.Q.; Yu, A.P.; Pollack, P.F.; Chao, J.; Mulani, P. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn’s disease: Patient-reported outcomes of the CHARM trial. Am. J. Gastroenterol., 2008, 103(12), 3132-3141. doi: 10.1111/j.1572-0241.2008.02175.x PMID: 18853973
  111. Menter, A.; Augustin, M.; Signorovitch, J.; Yu, A.P.; Wu, E.Q.; Gupta, S.R.; Bao, Y.; Mulani, P. The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: A randomized clinical trial. J. Am. Acad. Dermatol., 2010, 62(5), 812-818. doi: 10.1016/j.jaad.2009.07.022 PMID: 20219265
  112. Lim, S.H.; Kim, K.; Choi, C.I. Pharmacogenomics of monoclonal antibodies for the treatment of rheumatoid arthritis. J. Pers. Med., 2022, 12(8), 1265. doi: 10.3390/jpm12081265 PMID: 36013214
  113. Raison, C.L.; Rutherford, R.E.; Woolwine, B.J.; Shuo, C.; Schettler, P.; Drake, D.F.; Haroon, E.; Miller, A.H. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: The role of baseline inflammatory biomarkers. JAMA Psychiatry, 2013, 70(1), 31-41. doi: 10.1001/2013.jamapsychiatry.4 PMID: 22945416
  114. Weinberger, J.F.; Raison, C.L.; Rye, D.B.; Montague, A.R.; Woolwine, B.J.; Felger, J.C.; Haroon, E.; Miller, A.H. Inhibition of tumor necrosis factor improves sleep continuity in patients with treatment resistant depression and high inflammation. Brain Behav. Immun., 2015, 47, 193-200. doi: 10.1016/j.bbi.2014.12.016 PMID: 25529904
  115. Webers, C.; Stolwijk, C.; Schiepers, O.; Schoonbrood, T.; van Tubergen, A.; Landewé, R.; van der Heijde, D.; Boonen, A. Infliximab treatment reduces depressive symptoms in patients with ankylosing spondylitis: An ancillary study to a randomized controlled trial (ASSERT). Arthritis Res. Ther., 2020, 22(1), 225. doi: 10.1186/s13075-020-02305-w PMID: 32993799
  116. Goffe, B.; Cather, J.C. Etanercept: An overview. J. Am. Acad. Dermatol., 2003, 49(S2), 105-111. doi: 10.1016/mjd.2003.554 PMID: 12894133
  117. Kekow, J.; Moots, R.J.; Emery, P.; Durez, P.; Koenig, A.; Singh, A.; Pedersen, R.; Robertson, D.; Freundlich, B.; Sato, R. Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: The COMET trial. Ann. Rheum. Dis., 2010, 69(1), 222-225. doi: 10.1136/ard.2008.102509 PMID: 19293160
  118. Tyring, S.; Bagel, J.; Lynde, C.; Klekotka, P.; Thompson, E.H.Z.; Gandra, S.R.; Shi, Y.; Kricorian, G. Patient-reported outcomes in moderate-to-severe plaque psoriasis with scalp involvement: Results from a randomized, double-blind, placebo-controlled study of etanercept. J. Eur. Acad. Dermatol. Venereol., 2013, 27(1), 125-128. doi: 10.1111/j.1468-3083.2011.04394.x PMID: 22188302
  119. Sun, Y.; Wang, D.; Salvadore, G.; Hsu, B.; Curran, M.; Casper, C.; Vermeulen, J.; Kent, J.M.; Singh, J.; Drevets, W.C.; Wittenberg, G.M.; Chen, G. The effects of interleukin-6 neutralizing antibodies on symptoms of depressed mood and anhedonia in patients with rheumatoid arthritis and multicentric Castleman’s disease. Brain Behav. Immun., 2017, 66, 156-164. doi: 10.1016/j.bbi.2017.06.014 PMID: 28676350
  120. Narazaki, M.; Tanaka, T.; Kishimoto, T. The role and therapeutic targeting of IL-6 in rheumatoid arthritis. Expert Rev. Clin. Immunol., 2017, 13(6), 535-551. doi: 10.1080/1744666X.2017.1295850 PMID: 28494214
  121. Griffiths, C.E.M.; Fava, M.; Miller, A.H.; Russell, J.; Ball, S.G.; Xu, W.; Acharya, N.; Rapaport, M.H. Impact of ixekizumab treatment on depressive symptoms and systemic inflammation in patients with moderate-to-severe psoriasis: An integrated analysis of three phase 3 clinical studies. Psychother. Psychosom., 2017, 86(5), 260-267. doi: 10.1159/000479163 PMID: 28903122
  122. Wang, R.; Maksymowych, W.P. Targeting the interleukin-23/interleukin-17 inflammatory pathway: Successes and failures in the treatment of axial spondyloarthritis. Front. Immunol., 2021, 12, 715510. doi: 10.3389/fimmu.2021.715510 PMID: 34539646
  123. Kim, S.J.; Park, M.Y.; Pak, K.; Han, J.; Kim, G.W.; Kim, H.S.; Ko, H.C.; Kim, M.B.; Kim, B.S. Improvement of depressive symptoms in patients with moderate-to-severe psoriasis treated with ustekinumab: An open label trial validated using beck depression inventory, Hamilton depression rating scale measures and 18 fluorodeoxyglucose (FDG) positron emission tomography (PET). J. Dermatolog. Treat., 2018, 29(8), 761-768. doi: 10.1080/09546634.2018.1466021 PMID: 29658378
  124. Simpson, E.L.; Gadkari, A.; Worm, M.; Soong, W.; Blauvelt, A.; Eckert, L.; Wu, R.; Ardeleanu, M.; Graham, N.M.H.; Pirozzi, G.; Sutherland, E.R.; Mastey, V. Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD). J. Am. Acad. Dermatol., 2016, 75(3), 506-515. doi: 10.1016/j.jaad.2016.04.054 PMID: 27268421
  125. Cork, M.J.; Eckert, L.; Simpson, E.L.; Armstrong, A.; Barbarot, S.; Puig, L.; Girolomoni, G.; de Bruin-Weller, M.; Wollenberg, A.; Kataoka, Y.; Remitz, A.; Beissert, S.; Mastey, V.; Ardeleanu, M.; Chen, Z.; Gadkari, A.; Chao, J. Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: Analysis of pooled data from the randomized trials SOLO 1 and SOLO 2. J. Dermatolog. Treat., 2020, 31(6), 606-614. doi: 10.1080/09546634.2019.1612836 PMID: 31179791
  126. Zobdeh, F.; Eremenko, I.I.; Akan, M.A.; Tarasov, V.V.; Chubarev, V.N.; Schiöth, H.B.; Mwinyi, J. Pharmacogenetics and pain treatment with a focus on non-steroidal Anti-Inflammatory Drugs (NSAIDs) and antidepressants: A systematic review. Pharmaceutics, 2022, 14(6), 1190. doi: 10.3390/pharmaceutics14061190 PMID: 35745763
  127. Ozleyen, A.; Yilmaz, Y.B.; Donmez, S.; Atalay, H.N.; Antika, G.; Tumer, T.B. Looking at NSAIDs from a historical perspective and their current status in drug repurposing for cancer treatment and prevention. J. Cancer Res. Clin. Oncol., 2022, 1-19. doi: 10.1007/s00432-022-04187-8 PMID: 35876951
  128. Sinniah, A.; Yazid, S.; Flower, R.J. From NSAIDs to Glucocorticoids and Beyond. Cells, 2021, 10(12), 3524. doi: 10.3390/cells10123524 PMID: 34944032
  129. Flower, R.J. The development of COX2 inhibitors. Nat. Rev. Drug Discov., 2003, 2(3), 179-191. doi: 10.1038/nrd1034 PMID: 12612644
  130. Müller, N.; Schwarz, M.J.; Dehning, S.; Douhe, A.; Cerovecki, A.; Goldstein-Müller, B.; Spellmann, I.; Hetzel, G.; Maino, K.; Kleindienst, N.; Möller, H-J.; Arolt, V.; Riedel, M. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: Results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol. Psychiatry, 2006, 11(7), 680-684. doi: 10.1038/sj.mp.4001805 PMID: 16491133
  131. Akhondzadeh, S.; Jafari, S.; Raisi, F.; Nasehi, A.A.; Ghoreishi, A.; Salehi, B.; Mohebbi-Rasa, S.; Raznahan, M.; Kamalipour, A. Clinical trial of adjunctive celecoxib treatment in patients with major depression: A double blind and placebo controlled trial. Depress. Anxiety, 2009, 26(7), 607-611. doi: 10.1002/da.20589 PMID: 19496103
  132. Abbasi, S.H.; Hosseini, F.; Modabbernia, A.; Ashrafi, M.; Akhondzadeh, S. Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: Randomized double-blind placebo-controlled study. J. Affect. Disord., 2012, 141(2-3), 308-314. doi: 10.1016/j.jad.2012.03.033 PMID: 22516310
  133. Jafari, S.; Ashrafizadeh, S.G.; Zeinoddini, A.; Rasoulinejad, M.; Entezari, P.; Seddighi, S.; Akhondzadeh, S. Celecoxib for the treatment of mild-to-moderate depression due to acute brucellosis: A double-blind, placebo-controlled, randomized trial. J. Clin. Pharm. Ther., 2015, 40(4), 441-446. doi: 10.1111/jcpt.12287 PMID: 26009929
  134. Majd, M.; Hashemian, F.; Hosseini, S.M.; Vahdat Shariatpanahi, M.; Sharifi, A. A randomized, double-blind, placebo-controlled trial of celecoxib augmentation of sertraline in treatment of drug-naive depressed women: A pilot study. Iran. J. Pharm. Res., 2015, 14(3), 891-899. PMID: 26330878
  135. Alamdarsaravi, M.; Ghajar, A.; Noorbala, A.A.; Arbabi, M.; Emami, A.; Shahei, F.; Mirzania, M.; Jafarinia, M.; Afarideh, M.; Akhondzadeh, S. Efficacy and safety of celecoxib monotherapy for mild to moderate depression in patients with colorectal cancer: A randomized double-blind, placebo controlled trial. Psychiatry Res., 2017, 255, 59-65. doi: 10.1016/j.psychres.2017.05.029 PMID: 28528242
  136. Baune, B.T.; Sampson, E.; Louise, J.; Hori, H.; Schubert, K.O.; Clark, S.R.; Mills, N.T.; Fourrier, C. No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression: A 6-week double-blind placebo controlled randomized trial. Eur. Neuropsychopharmacol., 2021, 53, 34-46. doi: 10.1016/j.euroneuro.2021.07.092 PMID: 34375789
  137. Berk, M.; Woods, R.L.; Nelson, M.R.; Shah, R.C.; Reid, C.M.; Storey, E.; Fitzgerald, S.; Lockery, J.E.; Wolfe, R.; Mohebbi, M.; Dodd, S.; Murray, A.M.; Stocks, N.; Fitzgerald, P.B.; Mazza, C.; Agustini, B.; McNeil, J.J. Effect of aspirin vs placebo on the prevention of depression in older people. JAMA Psychiatry, 2020, 77(10), 1012-1020. doi: 10.1001/jamapsychiatry.2020.1214 PMID: 32492080
  138. Berk, M.; Mohebbi, M.; Dean, O.M.; Cotton, S.M.; Chanen, A.M.; Dodd, S.; Ratheesh, A.; Amminger, G.P.; Phelan, M.; Weller, A.; Mackinnon, A.; Giorlando, F.; Baird, S.; Incerti, L.; Brodie, R.E.; Ferguson, N.O.; Rice, S.; Schäfer, M.R.; Mullen, E.; Hetrick, S.; Kerr, M.; Harrigan, S.M.; Quinn, A.L.; Mazza, C.; McGorry, P.; Davey, C.G. Youth depression alleviation with anti-inflammatory agents (YoDA-A): A randomised clinical trial of rosuvastatin and aspirin. BMC Med., 2020, 18(1), 16. doi: 10.1186/s12916-019-1475-6 PMID: 31948461
  139. Mahagna, H.; Amital, D.; Amital, H. A randomised, double‐blinded study comparing giving etoricoxib vs. placebo to female patients with fibromyalgia. Int. J. Clin. Pract., 2016, 70(2), 163-170. doi: 10.1111/ijcp.12760 PMID: 26763773
  140. Fields, C.; Drye, L.; Vaidya, V.; Lyketsos, C.; Group, A.R. Celecoxib or naproxen treatment does not benefit depressive symptoms in persons age 70 and older: findings from a randomized controlled trial. Am. J. Geriatr. Psychiatry, 2012, 20(6), 505-513. doi: 10.1097/JGP.0b013e318227f4da PMID: 21775876
  141. Iyengar, R.L.; Gandhi, S.; Aneja, A.; Thorpe, K.; Razzouk, L.; Greenberg, J.; Mosovich, S.; Farkouh, M.E. NSAIDs are associated with lower depression scores in patients with osteoarthritis. Am. J. Med., 2013, 126(11), e1011-e1018. doi: 10.1016/j.amjmed.2013.02.037
  142. Mohammadinejad, P.; Arya, P.; Esfandbod, M.; Kaviani, A.; Najafi, M.; Kashani, L.; Zeinoddini, A.; Emami, S.A.; Akhondzadeh, S. Celecoxib versus diclofenac in mild to moderate depression management among breast cancer patients. Ann. Pharmacother., 2015, 49(9), 953-961. doi: 10.1177/1060028015592215 PMID: 26139640
  143. Plane, J.M.; Shen, Y.; Pleasure, D.E.; Deng, W. Prospects for minocycline neuroprotection. Arch. Neurol., 2010, 67(12), 1442-1448. doi: 10.1001/archneurol.2010.191 PMID: 20697034
  144. Bové, J.; Martínez-Vicente, M.; Vila, M. Fighting neurodegeneration with rapamycin: mechanistic insights. Nat. Rev. Neurosci., 2011, 12(8), 437-452. doi: 10.1038/nrn3068 PMID: 21772323
  145. Stock, M.L.; Fiedler, K.J.; Acharya, S.; Lange, J.K.; Mlynarczyk, G.S.A.; Anderson, S.J.; McCormack, G.R.; Kanuri, S.H.; Kondru, N.C.; Brewer, M.T.; Carlson, S.A. Antibiotics acting as neuroprotectants via mechanisms independent of their anti-infective activities. Neuropharmacology, 2013, 73, 174-182. doi: 10.1016/j.neuropharm.2013.04.059 PMID: 23748053
  146. Colovic, M.; Caccia, S. Liquid chromatographic determination of minocycline in brain-to-plasma distribution studies in the rat. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2003, 791(1-2), 337-343. doi: 10.1016/S1570-0232(03)00247-2 PMID: 12798193
  147. Emadi-Kouchak, H.; Mohammadinejad, P.; Asadollahi-Amin, A.; Rasoulinejad, M.; Zeinoddini, A.; Yalda, A.; Akhondzadeh, S. Therapeutic effects of minocycline on mild-to-moderate depression in HIV patients. Int. Clin. Psychopharmacol., 2016, 31(1), 20-26. doi: 10.1097/YIC.0000000000000098 PMID: 26465919
  148. Dean, O.M.; Kanchanatawan, B.; Ashton, M.; Mohebbi, M.; Ng, C.H.; Maes, M.; Berk, L.; Sughondhabirom, A.; Tangwongchai, S.; Singh, A.B.; McKenzie, H.; Smith, D.J.; Malhi, G.S.; Dowling, N.; Berk, M. Adjunctive minocycline treatment for major depressive disorder: A proof of concept trial. Aust. N. Z. J. Psychiatry, 2017, 51(8), 829-840. doi: 10.1177/0004867417709357 PMID: 28578592
  149. Husain, M.I.; Chaudhry, I.B.; Husain, N.; Khoso, A.B.; Rahman, R.R.; Hamirani, M.M.; Hodsoll, J.; Qurashi, I.; Deakin, J.F.W.; Young, A.H. Minocycline as an adjunct for treatment-resistant depressive symptoms: A pilot randomised placebo-controlled trial. J. Psychopharmacol., 2017, 31(9), 1166-1175. doi: 10.1177/0269881117724352 PMID: 28857658
  150. Nettis, M.A.; Lombardo, G.; Hastings, C.; Zajkowska, Z.; Mariani, N.; Nikkheslat, N.; Worrell, C.; Enache, D.; McLaughlin, A.; Kose, M.; Sforzini, L.; Bogdanova, A.; Cleare, A.; Young, A.H.; Pariante, C.M.; Mondelli, V. Augmentation therapy with minocycline in treatment-resistant depression patients with low-grade peripheral inflammation: Results from a double-blind randomised clinical trial. Neuropsychopharmacology, 2021, 46(5), 939-948. doi: 10.1038/s41386-020-00948-6 PMID: 33504955
  151. Attwells, S.; Setiawan, E.; Rusjan, P.M.; Xu, C.; Kish, S.J.; Vasdev, N.; Houle, S.; Santhirakumar, A.; Meyer, J.H. A double-blind placebo-controlled trial of minocycline on translocator protein distribution volume in treatment-resistant major depressive disorder. Transl. Psychiatry, 2021, 11(1), 334. doi: 10.1038/s41398-021-01450-3 PMID: 34052828
  152. Vézina, C.; Kudelski, A.; Sehgal, S.N. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J. Antibiot., 1975, 28(10), 721-726. doi: 10.7164/antibiotics.28.721 PMID: 1102508
  153. Ignácio, Z.M.; Réus, G.Z.; Arent, C.O.; Abelaira, H.M.; Pitcher, M.R.; Quevedo, J. New perspectives on the involvement of mTOR in depression as well as in the action of antidepressant drugs. Br. J. Clin. Pharmacol., 2016, 82(5), 1280-1290. doi: 10.1111/bcp.12845 PMID: 26613210
  154. Murrough, J.W.; Abdallah, C.G.; Mathew, S.J. Targeting glutamate signalling in depression: Progress and prospects. Nat. Rev. Drug Discov., 2017, 16(7), 472-486. doi: 10.1038/nrd.2017.16 PMID: 28303025
  155. Gould, T.D.; Zarate, C.A., Jr; Thompson, S.M. Molecular pharmacology and neurobiology of rapid-acting antidepressants. Annu. Rev. Pharmacol. Toxicol., 2019, 59(1), 213-236. doi: 10.1146/annurev-pharmtox-010617-052811 PMID: 30296896
  156. Abdallah, C.G.; Sanacora, G.; Duman, R.S.; Krystal, J.H. The neurobiology of depression, ketamine and rapid-acting antidepressants: Is it glutamate inhibition or activation? Pharmacol. Ther., 2018, 190, 148-158. doi: 10.1016/j.pharmthera.2018.05.010 PMID: 29803629
  157. Abdallah, C.G.; Averill, L.A.; Gueorguieva, R.; Goktas, S.; Purohit, P.; Ranganathan, M.; Sherif, M.; Ahn, K.H.; D’Souza, D.C.; Formica, R.; Southwick, S.M.; Duman, R.S.; Sanacora, G.; Krystal, J.H. Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin. Neuropsychopharmacology, 2020, 45(6), 990-997. doi: 10.1038/s41386-020-0644-9 PMID: 32092760
  158. Yaribeygi, H.; Ashrafizadeh, M.; Henney, N.C.; Sathyapalan, T.; Jamialahmadi, T.; Sahebkar, A. Neuromodulatory effects of anti-diabetes medications: A mechanistic review. Pharmacol. Res., 2020, 152, 104611. doi: 10.1016/j.phrs.2019.104611 PMID: 31863868
  159. García-Bueno, B.; Pérez-Nievas, B.G.; Leza, J.C. Is there a role for the nuclear receptor PPARγ in neuropsychiatric diseases? Int. J. Neuropsychopharmacol., 2010, 13(10), 1411-1429. doi: 10.1017/S1461145710000970 PMID: 20800014
  160. Sepanjnia, K.; Modabbernia, A.; Ashrafi, M.; Modabbernia, M.J.; Akhondzadeh, S. Pioglitazone adjunctive therapy for moderate-to-severe major depressive disorder: randomized double-blind placebo-controlled trial. Neuropsychopharmacology, 2012, 37(9), 2093-2100. doi: 10.1038/npp.2012.58 PMID: 22549115
  161. Lin, K.W.; Wroolie, T.E.; Robakis, T.; Rasgon, N.L. Adjuvant pioglitazone for unremitted depression: Clinical correlates of treatment response. Psychiatry Res., 2015, 230(3), 846-852. doi: 10.1016/j.psychres.2015.10.013 PMID: 26602230
  162. Rasgon, N.; Lin, K.W.; Lin, J.; Epel, E.; Blackburn, E. Telomere length as a predictor of response to Pioglitazone in patients with unremitted depression: A preliminary study. Transl. Psychiatry, 2016, 6(1), e709. doi: 10.1038/tp.2015.187 PMID: 26731446
  163. Miller, R.A.; Chu, Q.; Xie, J.; Foretz, M.; Viollet, B.; Birnbaum, M.J. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature, 2013, 494(7436), 256-260. doi: 10.1038/nature11808 PMID: 23292513
  164. Abdallah, M.S.; Mosalam, E.M.; Zidan, A.A.A.; Elattar, K.S.; Zaki, S.A.; Ramadan, A.N.; Ebeid, A.M. RETRACTED ARTICLE: The antidiabetic metformin as an adjunct to antidepressants in patients with major depressive disorder: A proof-of-concept, randomized, double-blind, placebo-controlled trial. Neurotherapeutics, 2020, 17(4), 1897-1906. doi: 10.1007/s13311-020-00878-7 PMID: 32500486
  165. Walker, A.J.; Kim, Y.; Borissiouk, I.; Rehder, R.; Dodd, S.; Morris, G.; Nierenberg, A.A.; Maes, M.; Fernandes, B.S.; Dean, O.M.; Williams, L.J.; Eyre, H.A.; Kim, S.W.; Zoungas, S.; Carvalho, A.F.; Berk, M. Statins: Neurobiological underpinnings and mechanisms in mood disorders. Neurosci. Biobehav. Rev., 2021, 128, 693-708. doi: 10.1016/j.neubiorev.2021.07.012 PMID: 34265321
  166. Köhler-Forsberg, O.; Otte, C.; Gold, S.M.; Østergaard, S.D. Statins in the treatment of depression: Hype or hope? Pharmacol. Ther., 2020, 215, 107625. doi: 10.1016/j.pharmthera.2020.107625 PMID: 32652185
  167. Zeiser, R. Immune modulatory effects of statins. Immunology, 2018, 154(1), 69-75. doi: 10.1111/imm.12902 PMID: 29392731
  168. Santanello, N.C.; Barber, B.L.; Applegate, W.B.; Elam, J.; Curtis, C.; Hunninghake, D.B.; Gordon, D.J. Effect of pharmacologic lipid lowering on health-related quality of life in older persons: Results from the Cholesterol Reduction in Seniors Program (CRISP) Pilot Study. J. Am. Geriatr. Soc., 1997, 45(1), 8-14. doi: 10.1111/j.1532-5415.1997.tb00971.x PMID: 8994481
  169. Ghanizadeh, A.; Hedayati, A. Augmentation of fluoxetine with lovastatin for treating major depressive disorder, a randomized double-blind placebo controlled-clinical trial. Depress. Anxiety, 2013, 30(11), 1084-1088. doi: 10.1002/da.22195 PMID: 24115188
  170. Stewart, R.A.; Sharples, K.J.; North, F.M.; Menkes, D.B.; Baker, J.; Simes, J. Long-term assessment of psychological well-being in a randomized placebo-controlled trial of cholesterol reduction with pravastatin. Arch. Intern. Med., 2000, 160(20), 3144-3152. doi: 10.1001/archinte.160.20.3144 PMID: 11074745
  171. Carlsson, C.M.; Papcke-Benson, K.; Carnes, M.; McBride, P.E.; Stein, J.H. Health-related quality of life and long-term therapy with pravastatin and tocopherol (vitamin E) in older adults. Drugs Aging, 2002, 19(10), 793-805. doi: 10.2165/00002512-200219100-00008 PMID: 12390056
  172. Gougol, A.; Zareh-Mohammadi, N.; Raheb, S.; Farokhnia, M.; Salimi, S.; Iranpour, N.; Yekehtaz, H.; Akhondzadeh, S. Simvastatin as an adjuvant therapy to fluoxetine in patients with moderate to severe major depression: A double-blind placebo-controlled trial. J. Psychopharmacol., 2015, 29(5), 575-581. doi: 10.1177/0269881115578160 PMID: 25827645
  173. Chan, D.; Binks, S.; Nicholas, J.M.; Frost, C.; Cardoso, M.J.; Ourselin, S.; Wilkie, D.; Nicholas, R.; Chataway, J. Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: Secondary analyses from the MS-STAT randomised, placebo-controlled trial. Lancet Neurol., 2017, 16(8), 591-600. doi: 10.1016/S1474-4422(17)30113-8 PMID: 28600189
  174. Haghighi, M.; Khodakarami, S.; Jahangard, L.; Ahmadpanah, M.; Bajoghli, H.; Holsboer-Trachsler, E.; Brand, S. In a randomized, double-blind clinical trial, adjuvant atorvastatin improved symptoms of depression and blood lipid values in patients suffering from severe major depressive disorder. J. Psychiatr. Res., 2014, 58, 109-114. doi: 10.1016/j.jpsychires.2014.07.018 PMID: 25130678
  175. Abbasi, S.H.; Mohammadinejad, P.; Shahmansouri, N.; Salehiomran, A.; Beglar, A.A.; Zeinoddini, A.; Forghani, S.; Akhondzadeh, S. Simvastatin versus atorvastatin for improving mild to moderate depression in post-coronary artery bypass graft patients: A double-blind, placebo-controlled, randomized trial. J. Affect. Disord., 2015, 183, 149-155. doi: 10.1016/j.jad.2015.04.049 PMID: 26005776
  176. Arana, G.W.; Santos, A.B.; Laraia, M.T.; McLeod-Bryant, S.; Beale, M.D.; Rames, L.J.; Roberts, J.M.; Dias, J.K.; Molloy, M. Dexamethasone for the treatment of depression: A randomized, placebo- controlled, double-blind trial. Am. J. Psychiatry, 1995, 152(2), 265-267. doi: 10.1176/ajp.152.2.265 PMID: 7840362
  177. DeBattista, C.; Posener, J.A.; Kalehzan, B.M.; Schatzberg, A.F. Acute antidepressant effects of intravenous hydrocortisone and CRH in depressed patients: A double-blind, placebo-controlled study. Am. J. Psychiatry, 2000, 157(8), 1334-1337. doi: 10.1176/appi.ajp.157.8.1334 PMID: 10910802
  178. Clayton, P.; Hill, M.; Bogoda, N.; Subah, S.; Venkatesh, R. Palmitoylethanolamide: A natural compound for health management. Int. J. Mol. Sci., 2021, 22(10), 5305. doi: 10.3390/ijms22105305 PMID: 34069940
  179. Ghazizadeh-Hashemi, M.; Ghajar, A.; Shalbafan, M.R.; Ghazizadeh-Hashemi, F.; Afarideh, M.; Malekpour, F.; Ghaleiha, A.; Ardebili, M.E.; Akhondzadeh, S. Palmitoylethanolamide as adjunctive therapy in major depressive disorder: A double-blind, randomized and placebo-controlled trial. J. Affect. Disord., 2018, 232, 127-133. doi: 10.1016/j.jad.2018.02.057 PMID: 29486338
  180. Liu, L.; Liu, C.; Wang, Y.; Wang, P.; Li, Y.; Li, B. Herbal medicine for anxiety, depression and insomnia. Curr. Neuropharmacol., 2015, 13(4), 481-493. doi: 10.2174/1570159X1304150831122734 PMID: 26412068
  181. Yeung, W.F.; Chung, K.F.; Ng, K.Y.; Yu, Y.M.; Ziea, E.T.C.; Ng, B.F.L. A systematic review on the efficacy, safety and types of Chinese herbal medicine for depression. J. Psychiatr. Res., 2014, 57, 165-175. doi: 10.1016/j.jpsychires.2014.05.016 PMID: 24974002
  182. Matias, J.N.; Achete, G.; Campanari, G.S.S.; Guiguer, É.L.; Araújo, A.C.; Buglio, D.S.; Barbalho, S.M. A systematic review of the antidepressant effects of curcumin: Beyond monoamines theory. Aust. N. Z. J. Psychiatry, 2021, 55(5), 451-462. doi: 10.1177/0004867421998795 PMID: 33673739
  183. Panahi, Y.; Badeli, R.; Karami, G.R.; Sahebkar, A. Investigation of the efficacy of adjunctive therapy with bioavailability-boosted curcuminoids in major depressive disorder. Phytother. Res., 2015, 29(1), 17-21. doi: 10.1002/ptr.5211 PMID: 25091591
  184. Lopresti, A.L.; Maes, M.; Meddens, M.J.M.; Maker, G.L.; Arnoldussen, E.; Drummond, P.D. Curcumin and major depression: A randomised, double-blind, placebo-controlled trial investigating the potential of peripheral biomarkers to predict treatment response and antidepressant mechanisms of change. Eur. Neuropsychopharmacol., 2015, 25(1), 38-50. doi: 10.1016/j.euroneuro.2014.11.015 PMID: 25523883
  185. Lopresti, A.L.; Maes, M.; Maker, G.L.; Hood, S.D.; Drummond, P.D. Curcumin for the treatment of major depression: A randomised, double-blind, placebo controlled study. J. Affect. Disord., 2014, 167, 368-375. doi: 10.1016/j.jad.2014.06.001 PMID: 25046624
  186. Sanmukhani, J.; Satodia, V.; Trivedi, J.; Patel, T.; Tiwari, D.; Panchal, B.; Goel, A.; Tripathi, C.B. Efficacy and safety of curcumin in major depressive disorder: A randomized controlled trial. Phytother. Res., 2014, 28(4), 579-585. doi: 10.1002/ptr.5025 PMID: 23832433
  187. Esmaily, H.; Sahebkar, A.; Iranshahi, M.; Ganjali, S.; Mohammadi, A.; Ferns, G.; Ghayour-Mobarhan, M. An investigation of the effects of curcumin on anxiety and depression in obese individuals: A randomized controlled trial. Chin. J. Integr. Med., 2015, 21(5), 332-338. doi: 10.1007/s11655-015-2160-z PMID: 25776839
  188. Yu, J.J.; Pei, L.B.; Zhang, Y.; Wen, Z.Y.; Yang, J.L. Chronic supplementation of curcumin enhances the efficacy of antidepressants in major depressive disorder. J. Clin. Psychopharmacol., 2015, 35(4), 406-410. doi: 10.1097/JCP.0000000000000352 PMID: 26066335
  189. Lopresti, A.L.; Drummond, P.D. Efficacy of curcumin, and a saffron/curcumin combination for the treatment of major depression: A randomised, double-blind, placebo-controlled study. J. Affect. Disord., 2017, 207, 188-196. doi: 10.1016/j.jad.2016.09.047 PMID: 27723543
  190. Kanchanatawan, B.; Tangwongchai, S.; Sughondhabhirom, A.; Suppapitiporn, S.; Hemrunrojn, S.; Carvalho, A.F.; Maes, M. Add-on treatment with curcumin has antidepressive effects in thai patients with major depression: Results of a randomized double-blind placebo-controlled study. Neurotox. Res., 2018, 33(3), 621-633. doi: 10.1007/s12640-017-9860-4 PMID: 29327213
  191. Bergman, J.; Miodownik, C.; Bersudsky, Y.; Sokolik, S.; Lerner, P.P.; Kreinin, A.; Polakiewicz, J.; Lerner, V. Curcumin as an add-on to antidepressive treatment: A randomized, double-blind, placebo-controlled, pilot clinical study. Clin. Neuropharmacol., 2013, 36(3), 73-77. doi: 10.1097/WNF.0b013e31828ef969 PMID: 23673908
  192. Cao, Z.Y.; Liu, Y.Z.; Li, J.M.; Ruan, Y.M.; Yan, W.J.; Zhong, S.Y.; Zhang, T.; Liu, L.L.; Wu, R.; Wang, B.; Wang, W.; Bi, X.Y.; Wang, Y.X.; Su, W.J.; Jiang, C.L. Glycyrrhizic acid as an adjunctive treatment for depression through anti-inflammation: A randomized placebo-controlled clinical trial. J. Affect. Disord., 2020, 265, 247-254. doi: 10.1016/j.jad.2020.01.048 PMID: 32090748
  193. Molendijk, M.; Molero, P.; Sánchez-Pedreño, O.F.; Van der Does, W.; Martínez-González, A.M. Diet quality and depression risk: A systematic review and dose-response meta-analysis of prospective studies. J. Affect. Disord., 2018, 226, 346-354. doi: 10.1016/j.jad.2017.09.022 PMID: 29031185
  194. Yang, Y.; Kim, Y.; Je, Y. Fish consumption and risk of depression: Epidemiological evidence from prospective studies. Asia-Pac. Psychiatry, 2018, 10(4), e12335. doi: 10.1111/appy.12335 PMID: 30238628
  195. Su, K.P.; Lai, H.C.; Yang, H.T.; Su, W.P.; Peng, C.Y.; Chang, J.P.C.; Chang, H.C.; Pariante, C.M. Omega-3 fatty acids in the prevention of interferon-alpha-induced depression: results from a randomized, controlled trial. Biol. Psychiatry, 2014, 76(7), 559-566. doi: 10.1016/j.biopsych.2014.01.008 PMID: 24602409
  196. Martins, J.G. EPA but not DHA appears to be responsible for the efficacy of omega-3 long chain polyunsaturated fatty acid supplementation in depression: evidence from a meta-analysis of randomized controlled trials. J. Am. Coll. Nutr., 2009, 28(5), 525-542. doi: 10.1080/07315724.2009.10719785 PMID: 20439549
  197. Ortega, M.A.; Fraile-Martínez, Ó.; García-Montero, C.; Alvarez-Mon, M.A.; Lahera, G.; Monserrat, J.; Llavero-Valero, M.; Gutiérrez-Rojas, L.; Molina, R.; Rodríguez-Jimenez, R.; Quintero, J.; De Mon, M.A. Biological role of nutrients, food and dietary patterns in the prevention and clinical management of major depressive disorder. Nutrients, 2022, 14(15), 3099. doi: 10.3390/nu14153099 PMID: 35956276
  198. Mee-inta, O.; Zhao, Z.W.; Kuo, Y.M. Physical exercise inhibits inflammation and microglial activation. Cells, 2019, 8(7), 691. doi: 10.3390/cells8070691 PMID: 31324021
  199. Ding, Y.; Xu, X. Anti-inflammatory effect of exercise training through reducing inflammasome activation-related inflammatory cytokine levels in overweight/obese populations: A systematic review and meta-analysis. Complement. Ther. Clin. Pract., 2022, 49, 101656. doi: 10.1016/j.ctcp.2022.101656 PMID: 36055106
  200. Lee, J.; Gierc, M.; Vila-Rodriguez, F.; Puterman, E.; Faulkner, G. Efficacy of exercise combined with standard treatment for depression compared to standard treatment alone: A systematic review and meta-analysis of randomized controlled trials. J. Affect. Disord., 2021, 295, 1494-1511. doi: 10.1016/j.jad.2021.09.043 PMID: 34565591
  201. Bigarella, L.G.; Ballotin, V.R.; Mazurkiewicz, L.F.; Ballardin, A.C.; Rech, D.L.; Bigarella, R.L.; Selistre, L.S. Exercise for depression and depressive symptoms in older adults: An umbrella review of systematic reviews and Meta-analyses. Aging Ment. Health, 2022, 26(8), 1503-1513. doi: 10.1080/13607863.2021.1951660 PMID: 34328049
  202. Xie, Y.; Wu, Z.; Sun, L.; Zhou, L.; Wang, G.; Xiao, L.; Wang, H. The effects and mechanisms of exercise on the treatment of depression. Front. Psychiatry, 2021, 12, 705559. doi: 10.3389/fpsyt.2021.705559 PMID: 34803752
  203. Marinovic, D.A.; Hunter, R.L. Examining the interrelationships between mindfulness‐based interventions, depression, inflammation, and cancer survival. CA Cancer J. Clin., 2022, 72(5), 490-502. doi: 10.3322/caac.21733 PMID: 35709081
  204. Sanada, K.; Montero-Marin, J.; Barceló-Soler, A.; Ikuse, D.; Ota, M.; Hirata, A.; Yoshizawa, A.; Hatanaka, R.; Valero, M.S.; Demarzo, M.; Campayo, J.G.; Iwanami, A. Effects of mindfulness-based interventions on biomarkers and low-grade inflammation in patients with psychiatric disorders: A meta-analytic review. Int. J. Mol. Sci., 2020, 21(7), 2484. doi: 10.3390/ijms21072484 PMID: 32260096
  205. Reangsing, C.; Punsuwun, S.; Schneider, J.K. Effects of mindfulness interventions on depressive symptoms in adolescents: A meta-analysis. Int. J. Nurs. Stud., 2021, 115, 103848. doi: 10.1016/j.ijnurstu.2020.103848 PMID: 33383273
  206. Haller, H.; Anheyer, D.; Cramer, H.; Dobos, G. Complementary therapies for clinical depression: An overview of systematic reviews. BMJ Open, 2019, 9(8), e028527. doi: 10.1136/bmjopen-2018-028527 PMID: 31383703
  207. Johannsen, M.; Nissen, E.R.; Lundorff, M.; O’Toole, M.S. Mediators of acceptance and mindfulness-based therapies for anxiety and depression: A systematic review and meta-analysis. Clin. Psychol. Rev., 2022, 94, 102156. doi: 10.1016/j.cpr.2022.102156 PMID: 35483275
  208. Köhler, O.; Benros, M.E.; Nordentoft, M.; Farkouh, M.E.; Iyengar, R.L.; Mors, O.; Krogh, J. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: A systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry, 2014, 71(12), 1381-1391. doi: 10.1001/jamapsychiatry.2014.1611 PMID: 25322082
  209. Adzic, M.; Brkic, Z.; Mitic, M.; Francija, E.; Jovicic, M.J.; Radulovic, J.; Maric, N.P. Therapeutic strategies for treatment of inflammation-related depression. Curr. Neuropharmacol., 2018, 16(2), 176-209. PMID: 28847294
  210. Kopschina Feltes, P.; Doorduin, J.; Klein, H.C.; Juárez-Orozco, L.E.; Dierckx, R.A.J.O.; Moriguchi-Jeckel, C.M.; de Vries, E.F.J. Anti-inflammatory treatment for major depressive disorder: Implications for patients with an elevated immune profile and non-responders to standard antidepressant therapy. J. Psychopharmacol., 2017, 31(9), 1149-1165. doi: 10.1177/0269881117711708 PMID: 28653857
  211. Shariq, A.S.; Brietzke, E.; Rosenblat, J.D.; Barendra, V.; Pan, Z.; McIntyre, R.S. Targeting cytokines in reduction of depressive symptoms: A comprehensive review. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2018, 83, 86-91. doi: 10.1016/j.pnpbp.2018.01.003 PMID: 29309829
  212. Malhi, G.S.; Outhred, T.; Hamilton, A.; Boyce, P.M.; Bryant, R.; Fitzgerald, P.B.; Lyndon, B.; Mulder, R.; Murray, G.; Porter, R.J.; Singh, A.B.; Fritz, K. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders: Major depression summary. Med. J. Aust., 2018, 208(4), 175-180. doi: 10.5694/mja17.00659 PMID: 29490210
  213. Undurraga, J.; Baldessarini, R.J. Randomized, placebo-controlled trials of antidepressants for acute major depression: Thirty-year meta-analytic review. Neuropsychopharmacology, 2012, 37(4), 851-864. doi: 10.1038/npp.2011.306 PMID: 22169941
  214. Matveychuk, D.; Thomas, R.K.; Swainson, J.; Khullar, A.; MacKay, M.A.; Baker, G.B.; Dursun, S.M. Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers. Ther. Adv. Psychopharmacol., 2020, 10. doi: 10.1177/2045125320916657 PMID: 32440333
  215. Nikkheslat, N. Targeting inflammation in depression: Ketamine as an anti-inflammatory antidepressant in psychiatric emergency. Brain Behav. Immun.-. Health, 2021, 18, 100383. doi: 10.1016/j.bbih.2021.100383 PMID: 34849492
  216. Li, J.M.; Liu, L.L.; Su, W.J.; Wang, B.; Zhang, T.; Zhang, Y.; Jiang, C.L. Ketamine may exert antidepressant effects via suppressing NLRP3 inflammasome to upregulate AMPA receptors. Neuropharmacology, 2019, 146, 149-153. doi: 10.1016/j.neuropharm.2018.11.022 PMID: 30496753
  217. Carvalho, A.F.; Sharma, M.S.; Brunoni, A.R.; Vieta, E.; Fava, G.A. The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: A critical review of the literature. Psychother. Psychosom., 2016, 85(5), 270-288. doi: 10.1159/000447034 PMID: 27508501
  218. Ahrnsbrak, R.; Stagnitti, M.N. Average expenditures per prescription antidepressant fill in the U.S. civilian noninstitutionalized population by select sociodemographic characteristics. In: Statistical Brief (Medical Expenditure Panel Survey (US); Rockville (MD), 2001.
  219. Shah, D.; Allen, L.; Zheng, W.; Madhavan, S.S.; Wei, W.; LeMasters, T.J.; Sambamoorthi, U. Economic burden of treatment-resistant depression among adults with chronic non-cancer pain conditions and major depressive disorder in the US. PharmacoEconomics, 2021, 39(6), 639-651. doi: 10.1007/s40273-021-01029-2 PMID: 33904144
  220. Kuehner, C. Why is depression more common among women than among men? Lancet Psychiatry, 2017, 4(2), 146-158. doi: 10.1016/S2215-0366(16)30263-2 PMID: 27856392
  221. Maslej, M.M.; Furukawa, T.A.; Cipriani, A.; Andrews, P.W.; Sanches, M.; Tomlinson, A.; Volkmann, C.; McCutcheon, R.A.; Howes, O.; Guo, X.; Mulsant, B.H. Individual differences in response to antidepressants. JAMA Psychiatry, 2021, 78(5), 490-497. doi: 10.1001/jamapsychiatry.2020.4564 PMID: 33595620
  222. Su, M.; Ouyang, X.; Song, Y. Neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, and monocyte to lymphocyte ratio in depression: A meta-analysis. J. Affect. Disord., 2022, 308, 375-383. doi: 10.1016/j.jad.2022.04.038 PMID: 35439466
  223. Cheng, Y.; Wang, Y.; Wang, X.; Jiang, Z.; Zhu, L.; Fang, S. Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and monocyte-to-lymphocyte ratio in depression: An updated systematic review and meta-analysis. Front. Psychiatry, 2022, 13, 893097. doi: 10.3389/fpsyt.2022.893097 PMID: 35782448
  224. Meng, F.; Yan, X.; Qi, J.; He, F. Association of neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, and monocyte to lymphocyte ratio with depression: A cross-sectional analysis of the NHANES data. J. Affect. Disord., 2022, 315, 168-173. doi: 10.1016/j.jad.2022.08.004 PMID: 35932936
  225. Schatzberg, A.F. Scientific issues relevant to improving the diagnosis, risk assessment, and treatment of major depression. Am. J. Psychiatry, 2019, 176(5), 342-347. doi: 10.1176/appi.ajp.2019.19030273 PMID: 31039643
  226. Li, J.M.; Jiang, C.L. Biological diagnosis of depression: A biomarker panel from several nonspecial indicators instead of the specific biomarker(s). Neuropsychiatr. Dis. Treat., 2022, 18, 3067-3071. doi: 10.2147/NDT.S393553 PMID: 36606185
  227. Franco, R.; Fernández-Suárez, D. Alternatively activated microglia and macrophages in the central nervous system. Prog. Neurobiol., 2015, 131, 65-86. doi: 10.1016/j.pneurobio.2015.05.003 PMID: 26067058
  228. Almolda, B.; de Labra, C.; Barrera, I.; Gruart, A.; Delgado-Garcia, J.M.; Villacampa, N.; Vilella, A.; Hofer, M.J.; Hidalgo, J.; Campbell, I.L.; González, B.; Castellano, B. Alterations in microglial phenotype and hippocampal neuronal function in transgenic mice with astrocyte-targeted production of interleukin-10. Brain Behav. Immun., 2015, 45, 80-97. doi: 10.1016/j.bbi.2014.10.015 PMID: 25449577
  229. Li, Z.; Ma, L.; Kulesskaya, N.; Võikar, V.; Tian, L. Microglia are polarized to M1 type in high-anxiety inbred mice in response to lipopolysaccharide challenge. Brain Behav. Immun., 2014, 38, 237-248. doi: 10.1016/j.bbi.2014.02.008 PMID: 24561490
  230. Zhang, L.; Zhang, J.; You, Z. Switching of the microglial activation phenotype is a possible treatment for depression disorder. Front. Cell. Neurosci., 2018, 12, 306. doi: 10.3389/fncel.2018.00306 PMID: 30459555
  231. Chhor, V.; Le Charpentier, T.; Lebon, S.; Oré, M.V.; Celador, I.L.; Josserand, J.; Degos, V.; Jacotot, E.; Hagberg, H.; Sävman, K.; Mallard, C.; Gressens, P.; Fleiss, B. Characterization of phenotype markers and neuronotoxic potential of polarised primary microglia in vitro. Brain Behav. Immun., 2013, 32, 70-85. doi: 10.1016/j.bbi.2013.02.005 PMID: 23454862
  232. Miki, A.; Honda, S.; Inoue, Y.; Yamada, Y.; Nakamura, M. Foveal depression and related factors in patients with a history of retinopathy of prematurity. Ophthalmologica, 2018, 240(2), 106-110. doi: 10.1159/000488368 PMID: 29742514
  233. Cherry, J.D.; Olschowka, J.A.; O’Banion, M.K. Neuroinflammation and M2 microglia: The good, the bad, and the inflamed. J. Neuroinflammation, 2014, 11(1), 98. doi: 10.1186/1742-2094-11-98 PMID: 24889886
  234. Kobayashi, K.; Imagama, S.; Ohgomori, T.; Hirano, K.; Uchimura, K.; Sakamoto, K.; Hirakawa, A.; Takeuchi, H.; Suzumura, A.; Ishiguro, N.; Kadomatsu, K. Minocycline selectively inhibits M1 polarization of microglia. Cell Death Dis., 2013, 4(3), e525. doi: 10.1038/cddis.2013.54 PMID: 23470532
  235. Cheng, Y.; Pardo, M.; Armini, R.S.; Martinez, A.; Mouhsine, H.; Zagury, J.F.; Jope, R.S.; Beurel, E. Stress-induced neuroinflammation is mediated by GSK3-dependent TLR4 signaling that promotes susceptibility to depression-like behavior. Brain Behav. Immun., 2016, 53, 207-222. doi: 10.1016/j.bbi.2015.12.012 PMID: 26772151
  236. Martin, M.; Rehani, K.; Jope, R.S.; Michalek, S.M. Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat. Immunol., 2005, 6(8), 777-784. doi: 10.1038/ni1221 PMID: 16007092
  237. Wu, T.Y.; Liu, L.; Zhang, W.; Zhang, Y.; Liu, Y.Z.; Shen, X.L.; Gong, H.; Yang, Y.Y.; Bi, X.Y.; Jiang, C.L.; Wang, Y.X. High-mobility group box-1 was released actively and involved in LPS induced depressive-like behavior. J. Psychiatr. Res., 2015, 64, 99-106. doi: 10.1016/j.jpsychires.2015.02.016 PMID: 25795092
  238. Gong, H.; Su, W.J.; Cao, Z.Y.; Lian, Y.J.; Peng, W.; Liu, Y.Z.; Zhang, Y.; Liu, L.L.; Wu, R.; Wang, B.; Zhang, T.; Wang, Y.X.; Jiang, C.L. Hippocampal Mrp8/14 signaling plays a critical role in the manifestation of depressive-like behaviors in mice. J. Neuroinflammation, 2018, 15(1), 252. doi: 10.1186/s12974-018-1296-0 PMID: 30180864
  239. Cao, X.; Li, L.P.; Wang, Q.; Wu, Q.; Hu, H.H.; Zhang, M.; Fang, Y.Y.; Zhang, J.; Li, S.J.; Xiong, W.C.; Yan, H.C.; Gao, Y.B.; Liu, J.H.; Li, X.W.; Sun, L.R.; Zeng, Y.N.; Zhu, X.H.; Gao, T.M. Astrocyte-derived ATP modulates depressive-like behaviors. Nat. Med., 2013, 19(6), 773-777. doi: 10.1038/nm.3162 PMID: 23644515
  240. Rana, T.; Behl, T.; Mehta, V.; Uddin, M.S.; Bungau, S. Molecular insights into the therapeutic promise of targeting HMGB1 in depression. Pharmacol. Rep., 2021, 73(1), 31-42. doi: 10.1007/s43440-020-00163-6 PMID: 33015736
  241. Wang, B.; Huang, X.; Pan, X.; Zhang, T.; Hou, C.; Su, W.J.; Liu, L.L.; Li, J.M.; Wang, Y.X. Minocycline prevents the depressive-like behavior through inhibiting the release of HMGB1 from microglia and neurons. Brain Behav. Immun., 2020, 88, 132-143. doi: 10.1016/j.bbi.2020.06.019 PMID: 32553784
  242. Wang, B.; Lian, Y.J.; Su, W.J.; Peng, W.; Dong, X.; Liu, L.L.; Gong, H.; Zhang, T.; Jiang, C.L.; Wang, Y.X. HMGB1 mediates depressive behavior induced by chronic stress through activating the kynurenine pathway. Brain Behav. Immun., 2018, 72, 51-60. doi: 10.1016/j.bbi.2017.11.017 PMID: 29195782
  243. Wang, B.; Lian, Y.J.; Dong, X.; Peng, W.; Liu, L.L.; Su, W.J.; Gong, H.; Zhang, T.; Jiang, C.L.; Li, J.S.; Wang, Y.X. Glycyrrhizic acid ameliorates the kynurenine pathway in association with its antidepressant effect. Behav. Brain Res., 2018, 353, 250-257. doi: 10.1016/j.bbr.2018.01.024 PMID: 29366745
  244. Lian, Y.J.; Gong, H.; Wu, T.Y.; Su, W.J.; Zhang, Y.; Yang, Y.Y.; Peng, W.; Zhang, T.; Zhou, J.R.; Jiang, C.L.; Wang, Y.X. Ds-HMGB1 and fr-HMGB induce depressive behavior through neuroinflammation in contrast to nonoxid-HMGB1. Brain Behav. Immun., 2017, 59, 322-332. doi: 10.1016/j.bbi.2016.09.017 PMID: 27647532
  245. Paik, S.; Kim, J.K.; Silwal, P.; Sasakawa, C.; Jo, E.K. An update on the regulatory mechanisms of NLRP3 inflammasome activation. Cell. Mol. Immunol., 2021, 18(5), 1141-1160. doi: 10.1038/s41423-021-00670-3 PMID: 33850310
  246. Kaufmann, F.N.; Costa, A.P.; Ghisleni, G.; Diaz, A.P.; Rodrigues, A.L.S.; Peluffo, H.; Kaster, M.P. NLRP3 inflammasome-driven pathways in depression: Clinical and preclinical findings. Brain Behav. Immun., 2017, 64, 367-383. doi: 10.1016/j.bbi.2017.03.002 PMID: 28263786
  247. Zhang, Y.; Liu, L.; Peng, Y.L.; Liu, Y.Z.; Wu, T.Y.; Shen, X.L.; Zhou, J.R.; Sun, D.Y.; Huang, A.J.; Wang, X.; Wang, Y.X.; Jiang, C.L. Involvement of inflammasome activation in lipopolysaccharide-induced mice depressive-like behaviors. CNS Neurosci. Ther., 2014, 20(2), 119-124. doi: 10.1111/cns.12170 PMID: 24279434
  248. Su, W.J.; Zhang, Y.; Chen, Y.; Gong, H.; Lian, Y.J.; Peng, W.; Liu, Y.Z.; Wang, Y.X.; You, Z.L.; Feng, S.J.; Zong, Y.; Lu, G.C.; Jiang, C.L. NLRP3 gene knockout blocks NF-kappaB and MAPK signaling pathway in CUMS-induced depression mouse model. Behav Brain Res, 2017, 322(Pt A), 1-8.
  249. Zhang, Y.; Liu, L.; Liu, Y.Z.; Shen, X.L.; Wu, T.Y.; Zhang, T.; Wang, W.; Wang, Y.X.; Jiang, C.L. NLRP3 inflammasome mediates chronic mild stress-induced depression in mice via neuroinflammation. Int. J. Neuropsychopharmacol., 2015, 18(8), pyv006-pyv006. doi: 10.1093/ijnp/pyv006 PMID: 25603858
  250. Su, W.J.; Peng, W.; Gong, H.; Liu, Y.Z.; Zhang, Y.; Lian, Y.J.; Cao, Z.Y.; Wu, R.; Liu, L.L.; Wang, B.; Wang, Y.X.; Jiang, C.L. Antidiabetic drug glyburide modulates depressive-like behavior comorbid with insulin resistance. J. Neuroinflammation, 2017, 14(1), 210. doi: 10.1186/s12974-017-0985-4 PMID: 29084550
  251. Xia, C.Y.; Guo, Y.X.; Lian, W.W.; Yan, Y.; Ma, B.Z.; Cheng, Y.C.; Xu, J.K.; He, J.; Zhang, W.K. The NLRP3 inflammasome in depression: Potential mechanisms and therapies. Pharmacol. Res., 2023, 187, 106625. doi: 10.1016/j.phrs.2022.106625 PMID: 36563870
  252. Li, W.; Niu, L.; Liu, Z.; Xu, X.; Shi, M.; Zhang, Y.; Deng, Y.; He, J.; Xu, Y.; Wan, W.; Sun, Q.; Zhong, X.; Cao, W. Inhibition of the NLRP3 inflammasome with MCC950 prevents chronic social isolation-induced depression-like behavior in male mice. Neurosci. Lett., 2021, 765, 136290. doi: 10.1016/j.neulet.2021.136290 PMID: 34644625
  253. Wang, D.; Wang, H.; Gao, H.; Zhang, H.; Zhang, H.; Wang, Q.; Sun, Z. P2X7 receptor mediates NLRP3 inflammasome activation in depression and diabetes. Cell Biosci., 2020, 10(1), 28. doi: 10.1186/s13578-020-00388-1 PMID: 32166013
  254. Yue, N.; Huang, H.; Zhu, X.; Han, Q.; Wang, Y.; Li, B.; Liu, Q.; Wu, G.; Zhang, Y.; Yu, J. Activation of P2X7 receptor and NLRP3 inflammasome assembly in hippocampal glial cells mediates chronic stress-induced depressive-like behaviors. J. Neuroinflammation, 2017, 14(1), 102. doi: 10.1186/s12974-017-0865-y PMID: 28486969
  255. Bhattacharya, A.; Lord, B.; Grigoleit, J.S.; He, Y.; Fraser, I.; Campbell, S.N.; Taylor, N.; Aluisio, L.; O’Connor, J.C.; Papp, M.; Chrovian, C.; Carruthers, N.; Lovenberg, T.W.; Letavic, M.A. Neuropsychopharmacology of JNJ-55308942: Evaluation of a clinical candidate targeting P2X7 ion channels in animal models of neuroinflammation and anhedonia. Neuropsychopharmacology, 2018, 43(13), 2586-2596. doi: 10.1038/s41386-018-0141-6 PMID: 30026598
  256. Farooq, R.K.; Tanti, A.; Ainouche, S.; Roger, S.; Belzung, C.; Camus, V.A. P2X7 receptor antagonist reverses behavioural alterations, microglial activation and neuroendocrine dysregulation in an unpredictable chronic mild stress (UCMS) model of depression in mice. Psychoneuroendocrinology, 2018, 97, 120-130. doi: 10.1016/j.psyneuen.2018.07.016 PMID: 30015007
  257. Liu, L.L.; Li, J.M.; Su, W.J.; Wang, B.; Jiang, C.L. Sex differences in depressive-like behaviour may relate to imbalance of microglia activation in the hippocampus. Brain Behav. Immun., 2019, 81, 188-197. doi: 10.1016/j.bbi.2019.06.012 PMID: 31181346
  258. Drevets, W.C.; Wittenberg, G.M.; Bullmore, E.T.; Manji, H.K. Immune targets for therapeutic development in depression: towards precision medicine. Nat. Rev. Drug Discov., 2022, 21(3), 224-244. doi: 10.1038/s41573-021-00368-1 PMID: 35039676
  259. Cattaneo, A.; Ferrari, C.; Turner, L.; Mariani, N.; Enache, D.; Hastings, C.; Kose, M.; Lombardo, G.; McLaughlin, A.P.; Nettis, M.A.; Nikkheslat, N.; Sforzini, L.; Worrell, C.; Zajkowska, Z.; Cattane, N.; Lopizzo, N.; Mazzelli, M.; Pointon, L.; Cowen, P.J.; Cavanagh, J.; Harrison, N.A.; de Boer, P.; Jones, D.; Drevets, W.C.; Mondelli, V.; Bullmore, E.T.; Pariante, C.M. Whole-blood expression of inflammasome- and glucocorticoid-related mRNAs correctly separates treatment-resistant depressed patients from drug-free and responsive patients in the BIODEP study. Transl. Psychiatry, 2020, 10(1), 232. doi: 10.1038/s41398-020-00874-7 PMID: 32699209
  260. Leday, G.G.R.; Vértes, P.E.; Richardson, S.; Greene, J.R.; Regan, T.; Khan, S.; Henderson, R.; Freeman, T.C.; Pariante, C.M.; Harrison, N.A.; Perry, V.H.; Drevets, W.C.; Wittenberg, G.M.; Bullmore, E.T.; Bullmore, E.; Vertes, P.; Cardinal, R.; Richardson, S.; Leday, G.; Freeman, T.; Regan, T.; Hume, D.; Wu, Z.; Pariante, C.; Cattaneo, A.; Zunszain, P.; Borsini, A.; Stewart, R.; Chandran, D.; Carvalho, L.; Bell, J.; Souza-Teodoro, L.; Perry, H.; Harrison, N.; Drevets, W.; Wittenberg, G.; Jones, D.; Bullmore, E.; Khan, S.; Stylianou, A.; Henderson, R. Replicable and coupled changes in innate and adaptive immune gene expression in two case-control studies of blood microarrays in major depressive disorder. Biol. Psychiatry, 2018, 83(1), 70-80. doi: 10.1016/j.biopsych.2017.01.021 PMID: 28688579
  261. van Eeden, W.A.; van Hemert, A.M.; Carlier, I.V.E.; Penninx, B.W.J.H.; Lamers, F.; Fried, E.I.; Schoevers, R.; Giltay, E.J. Basal and LPS-stimulated inflammatory markers and the course of individual symptoms of depression. Transl. Psychiatry, 2020, 10(1), 235. doi: 10.1038/s41398-020-00920-4 PMID: 32669537
  262. Spijker, S.; Van Zanten, J.S.; De Jong, S.; Penninx, B.W.J.H.; van Dyck, R.; Zitman, F.G.; Smit, J.H.; Ylstra, B.; Smit, A.B.; Hoogendijk, W.J.G. Stimulated gene expression profiles as a blood marker of major depressive disorder. Biol. Psychiatry, 2010, 68(2), 179-186. doi: 10.1016/j.biopsych.2010.03.017 PMID: 20471630
  263. Lucido, M.J.; Bekhbat, M.; Goldsmith, D.R.; Treadway, M.T.; Haroon, E.; Felger, J.C.; Miller, A.H. Aiding and abetting anhedonia: Impact of inflammation on the brain and pharmacological implications. Pharmacol. Rev., 2021, 73(3), 1084-1117. doi: 10.1124/pharmrev.120.000043 PMID: 34285088

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers